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Abstract
Structure-activity relationship (SAR) analysis of small bioactive compounds
is a key task in medicinal chemistry. Traditionally, SARs were established on
a case-by-case basis. However, with the arrival of high-throughput screening
(HTS) and synthesis techniques, a surge in the size and structural heterogeneity
of compound data is seen and the use of computational methods to analyse
SARs has become imperative and valuable.
In recent years, graphical methods have gained prominence for analysing
SARs. The choice of molecular representation and the method of assessing
similarities affects the outcome of the SAR analysis. Thus, alternative meth-
ods providing distinct points of view of SARs are required. In this thesis, a
novel graphical representation utilizing the canonical scaffold-skeleton defini-
tion to explore meaningful global and local SAR patterns in compound data is
introduced.
Furthermore, efforts have been made to go beyond descriptive SAR analysis
offered by the graphical methods. SAR features inferred from descriptive meth-
ods are utilized for compound activity predictions. In this context, a data struc-
ture called SAR matrix (SARM), which is reminiscent of conventional R-group
tables, is utilized. SARMs suggest many virtual compounds that represent as
of yet unexplored chemical space. These virtual compounds are candidates for
further exploration but are too many to prioritize simply on the basis of visual
inspection. Conceptually different approaches to enable systematic compound
prediction and prioritization are introduced. Much emphasis is put on evolving
the predictive ability for prospective compound design. Going beyond SAR
analysis, the SARM method has also been adapted to navigate multi-target
spaces primarily for analysing compound promiscuity patterns. Thus, the orig-
inal SARM methodology has been further developed for a variety of medicinal
chemistry and chemogenomics applications.
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Chapter 1
Introduction
The modern drug discovery process is a complex multistage process that focuses
on the development of novel drugs, i.e., chemical entities that elicit a desired
response in the biological system by acting on target(s) of interest. The struc-
ture of these small molecules plays an important role in their interactions with
corresponding biological target(s). Understanding the structure-activity rela-
tionships (SARs) of bioactive molecules is a key task in medicinal chemistry.1,2
Since the 1960s, computational approaches have been deployed for SAR ex-
ploration.2 A central principle that underlies SAR analysis is the “similarity
property principle” (SPP) which states that similar molecules should have sim-
ilar properties.3 The description of molecular structures and the assessment of
molecular similarities is critical for conducting relevant SAR studies and ob-
taining meaningful results.
Molecular Representations and Similarity
The SPP principle is not easy to capture methodologically because the problem
lies in defining (dis)similarity in a consistent manner. The assessment of struc-
tural similarity of compounds depends on the computational representation of
molecules and the similarity metric. Hence, the choice of the representation
and similarity metric influences SAR analysis.4
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The simplest way to represent a molecule is by its empirical formula. This
is a one-dimensional (1D) representation. However, one formula represents
multiple molecules because it does not contain structural information. Linear
notations such as Simplified Molecular Input Line Entry System (SMILES)5
have been developed, which represent the structural information of molecules
in an unambiguous, reproducible and universal manner.
A more intuitive and popular way to represent a molecule is to use its
two-dimensional (2D) molecular graph. In a graph, atoms are represented as
nodes using atomic symbols and edges correspond to bonds. Hence, the graph
represents the topology of the molecule and can be encoded in the form of a
connection table. This connection table comprises a sequential list of atoms
and a list of bonds connecting these atoms.
Molecules can also be represented in three dimensions (3D) by accounting
for the spatial arrangement of their atoms.
Molecular Descriptors
In computational medicinal chemistry, there is no gold standard by which
molecules should be represented. One of the most widely used ways is the
application of molecular descriptors. Molecular descriptors are mathemati-
cal functions that characterize structural and/or physicochemical properties
of molecules as numerical values. With the help of these numerical descriptors
computational chemical reference spaces in which molecules are projected can
be generated.6 Chemical (dis)similarity is then defined through the intermolec-
ular distance in the space.
A large number of descriptors have been defined that vary in complexity.7
In general, descriptors can be classified based on the dimensionality of the
molecular representations from which they are calculated. For example, 1D
descriptors include molecular weight and atom counts, such as the number of
carbon or oxygen atoms. These descriptors are calculated from 1D representa-
tion of molecules (chemical formula). 2D descriptors are derived on the basis of
2D molecular graphs that characterize, for example, physicochemical or topo-
logical properties, such as octanol/water partition coefficient (logP) or various
2
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topological indices. 3D descriptors are generated from 3D conformations, such
as pharmacophores and surface area.
Molecular Fingerprints
Apart from numerical representations of molecular structures and properties,
bit string representations are also popular. Molecular fingerprints (FPs) are
bit string representations of chemical structures and properties, which are often
encoded in binary formats. The presence and absence of a given feature in the
molecule is indicated by setting the corresponding bit to 1 and to 0, respectively.
As with numerical descriptors, FPs can be categorized into 2D or 3D depend-
ing on whether the chemical features describing the bit positions are derived
from 2D or 3D molecular graph representations. Over the past decades, various
FPs have been introduced that vary in their design, composition and length,
based on which different FP prototypes can be defined.8
FPs in which each feature is assigned to a specific bit position are called
keyed FPs. These FPs usually have fixed length, such as Molecular ACCess
System (MACCS)9 that contains 166 predefined structural fragments (substruc-
tures).
By contrast, combinatorial FPs capture layered atom environments in mole-
cules up to a predefined bond diameter. Instead of predefined feature sets,
molecule-specific features are calculated from individual compounds and thus
the corresponding FPs would have a variable length. In addition, each feature
is hashed into an integer number that represents the final feature set for a
molecule. The most popular combinatorial FPs are the extended connectivity
FPs (ECFPs).10 An important feature of combinatorial FPs is that they capture
atom environments in a molecule.
Pharmacophore patterns can be captured by pharmacophore FPs. “Phar-
macophores are 3D (or 2D) arrangement of groups (functionalities) in a com-
pound responsible for its bioactivity”.8 In pharmacophore FPs, bit positions
are assigned to possible pharmacophore patterns encoded by conformers of a
molecule. Pharmacophore patterns are typically defined by triplet or quadru-
plet feature points and inter-feature distance ranges. These FPs typically con-
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tain very large number of bit positions. A comparison of the three different
types of FPs is presented in Figure 1.1. For a common molecule three different
FP representations are encoded as bit strings.
1. Layer c 
2. Layer cc(c)C  
3. Layer nc(N)c(C=0(N))cn) 
... 
Keyed FP Combinatorial FP Pharmacophore FP 
H 
H 11 
A 
8 
5 Ar 
H 
D 
13 
5 
7 
Figure 1.1: Molecular fingerprints. Three different (keyed, combinatorial and pharma-
cophore) FP designs are shown. Structural information used to obtain the corresponding FP
representation is highlighted. Blue- and white-colored bits indicate the presence and absence,
respectively, of specific structural features or arrangements in the molecule. Taken from [8].
A number of similarity metrics are available to quantitatively assess simi-
larity between a pair of molecular FPs.11 The underlying concept is to account
for common and distinct structural features. The most widely applied measure
is the Tanimoto coefficient (Tc)11 that counts the number of bits common to
two binary FPs with respect to the total number of unique bits that are set on
in each FP. Accordingly, the Tc for two binary FP representations A and B is
calculated as follows:
Tc(A,B) =
c
a+ b− c
where c is the number of bits set on in both FPs and a and b refer to the number
of bits set on in A and B, respectively. Tc value ranges between 0 and 1, where
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0 corresponds to no FP overlap and 1 to identical FPs. However, it should be
noted that identical FPs do not necessarily correspond to identical molecules
because FPs are only a generalization of the molecular structures.
Depending on the FP one uses, it is very difficult to decide whether a given
Tc value indicates the presence of “significant similarity” or not.4,12 Further-
more, it is difficult to relate specific structural changes in pairs of molecules
to quantified similarity values. Thus, the FP-based similarity measure is often
difficult for medicinal chemists to use. Substructure-based representations can
be chemically more intuitive to relate SARs and guide novel compound designs.
Molecular Scaffolds
The concept of scaffolds, which is popular in medicinal chemistry, accounts for
a substructure-based representation of molecules. Scaffolds are generally used
to describe core structures of molecules that are utilized in drug design or used
as building blocks for compound synthesis.13
Many different definitions of scaffolds exist. The most widely used defini-
tion was introduced by Bemis and Murcko.14 Bemis and Murcko (BM) scaffolds
are generated by removing all side chains from the molecules and retaining
ring systems and linkers. This enables the consistent generation of scaffolds
and provides a sound basis for molecular framework-based SAR analysis. Fol-
lowing this definition, multiple BM scaffolds with minor differences in their
heteroatoms and/or bond orders, are considered structurally distinct. BM scaf-
folds can be further abstracted to “cyclic skeletons” (CSKs)15 by changing each
heteroatom to carbon and setting all double, triple and aromatic bonds to sin-
gle bonds. Thus, topologically equivalent BM scaffolds are represented by a
common CSK. Figure 1.2 illustrates the compound-scaffold-skeleton hierarchy.
Each scaffold represents one or more compounds and each CSK covers one or
more scaffolds that share the same topology.
BM scaffolds and CSKs have been used to analyze the diversity of known
drugs13,14 and SAR trends in compound data.16,17 However, the hierarchical
scaffold definition has limitations. For example, the addition of a ring to an
existing BM scaffold creates per definition a distinct BM scaffold even though
5
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such modifications are commonly applied during lead optimization.13 Moreover,
the nature and properties of substituents attached to the scaffolds that often
influence the SARs are not accounted for. Hence, an alternative representation
is required that accounts for well-defined substructural relationships.
CSK 
Compound 
BM Scaffold 
Figure 1.2: Molecular framework A schematic diagram of the hierarchical generation of
Bemis and Murcko (BM) scaffolds and cyclic skeleton (CSK) from three compounds is shown.
BM scaffolds (red) are generated by removing all side chains and retaining only the rings and
linkers of the compounds. BM scaffolds are further converted to CSK by substituting all
heteroatoms to carbon and setting bond orders to one.
Matched Molecular Pairs
Substructural relationships between pairs of compounds can be elegantly cap-
tured by the concept of matched molecular pairs (MMPs).18 An MMP is a
pair of compounds that share a large substructure and differ by a structural
change (R-group) at a common site.18 An exemplary MMP is given in Figure
1.3. The MMP formalism provides a consistent and well-defined framework
to assess structural similarity. It helps in correlating structural changes to ac-
tivity/property changes in a systematic manner as compared to FPs or BM
scaffolds. The MMP concept has gained wide recognition in the medicinal
chemistry field.19
6
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MMP 
Transformation 
Figure 1.3: Matched molecular pair. A pair of compounds that forms a matched
molecular pair (MMP) is shown. The exchanged substituent is highlighted in red and the
corresponding transformation is depicted at the bottom.
Different algorithms that systematically extract MMPs from compound data
sets are available. Some algorithms utilize direct graph comparison like max-
imum common substructure (MCS) search between pairs of molecules.20 The
MCS search is an NP-hard problem21 and requires comparison of molecules in
a pairwise manner.22 Other algorithms involve fragmenting molecules into sub-
structures on the basis of pre-defined rules.23 The fragmentation step is comple-
mented by subsequent indexing of the identified fragments. The fragmentation
is carried out systematically on all single acyclic bonds present between two
non-hydrogen atoms in a molecule. The resulting larger fragments are stored
as keys and the remaining smaller fragments as values in the index table. If
a key fragment already exists, the corresponding value fragment is added to
the value list. Thus, the key fragment corresponds to the common substruc-
ture shared between the two molecules and the value fragments correspond to
the exchange of a pair of substructures, termed chemical transformations,23 as
shown in Figure 1.3. The fragmentation approach is computationally more effi-
cient for large-scale MMP extraction than MCS search. Furthermore, the MMP
definition has also been extended to include chemical changes at more than one
position by fragmenting molecules at multiple acyclic bonds (typically up to
three).19
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In order to assess compound pairs that are only distinguished by a func-
tional group or a single ring system “transformation size-restricted MMPs”
have been introduced.24 Such MMPs are useful for correlating small structural
modifications to activity/property changes.
A recent work has introduced the concept of “fuzzy matched pairs” (FMP)25
that combines the classical MMP definition with a pharmacophore description.
This enables the analysis of compound pairs with transformations that are
structurally distinct but share a pharmacophore.
The methods described in this section are different ways to represent molecules
and assess their similarity. Each method has its own advantages and limitations.
The exploration of SARs is affected by the choice of the representation and the
similarity metric. Other factors, such as the origin, composition and size of the
compound data set under investigation also affect the analysis of SARs. These
factors need to be considered when choosing the method for the analysis of
SARs.
SAR Analysis Methods
Current computational approaches to study SARs are multifaceted and of dif-
ferent methodological complexity. In general, the methodologies could be clas-
sified as descriptive or predictive. Descriptive approaches mine the SAR infor-
mation from the data and then represent it numerically or graphically. The
represented SARs can then be analyzed by medicinal chemists. Predictive ap-
proaches extract generalized SAR patterns from the reference compounds to
predict biological activities of new compounds.4
The field referred to as quantitative SAR (QSAR) analysis, was first devel-
oped by Hansch et al.26 and has been invaluable for understanding SARs. In
QSAR, a mathematical model is derived that relates structural features and/or
molecular properties to bioactivity. QSAR models are built from a set of com-
pounds with known biological activity. These models can be applied to predict
8
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activities of candidate molecules with a structural/chemical composition sim-
ilar to that of the reference compounds. Candidate compounds that are not
reasonably similar to some reference compounds fall outside the applicability
domain of the model and their activity cannot be reliably predicted.27
Over the years, QSAR modeling has evolved from applications using rel-
atively simple linear regression methods to more complex non-linear machine
learning techniques.28 However, even in the presence of similar compounds these
methods fail to reliably predict activities of the candidate compounds in many
cases.29 Outliers result not only from statistical fluctuations or measurement
errors but also from the limitation on the part of the SPP principle underlying
these approaches. SPP is intuitive and a central paradigm in medicinal chem-
istry, however, it is frequently observed that small modifications in chemical
structures can lead to dramatic changes in compound activity.29 Pairs of com-
pounds that show high structural similarity and significant difference in activity
are called activity cliffs29 and represent exceptions to the SPP principle.
These observations suggest that there are fundamental differences in the
nature of SARs. To deconvolute the complex SAR patterns in the data, de-
scriptive approaches have been used. These methods guide compound design
in hit-to-lead and lead optimization campaigns by enabling the user to under-
stand on a case-by-case basis the structural features that determine activity. A
conventional data structure called R-group table that displays the substituents
of individual compounds and their corresponding compound activity is useful
to study the effect of small structural changes on compound potency. How-
ever, R-group tables are applied to analogs that share the same core structure
and are not suitable to analyze large compound sets. Therefore, tools that
can be applied on large and structurally heterogeneous compound data sets are
indispensable.
Activity Landscapes
The descriptive approaches for SAR analysis include various data mining and
visualization methods to systematically analyze SARs on a large-scale and ex-
9
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tract available SAR information from compound data sets of different sizes and
origins.30 The combination of these methods provides a basis for the exploration
of SARs.
The activity landscape concept is an approach that has become popular.4,30
An activity landscape can be defined as any graphical representation that inte-
grates similarity and potency relationships between compounds having a specific
biological activity.4 It enables the systematic comparison of compound struc-
tures and their potencies.
The Nature of SARs
The different natures of SARs can be observed in 3D activity landscapes. A 3D
activity landscape is generated by adding activity as the third dimension to a
2D chemical reference space of a set of compounds.31 In the 2D chemical space,
inter-compound distances reflect structural (dis)similarity. Thus, compounds
that are close in the 2D space are chemically more similar than compounds
that are farther apart. The third dimension, activity, provides information
about the distribution of the compounds’ potency values. Compounds with
large or moderate differences in their potency value can be clearly observed.
The activity landscape view resembles geographical landscapes, and contains
similar features, e.g. plains, mountains and valleys.
In 3D representations, gently sloped areas, as shown in Figure 1.4a, repre-
sent regions of SAR continuity where gradual changes in chemical structure are
accompanied by small or moderate changes in potency.2,4 By contrast, rugged
areas, as shown in Figure 1.4b, represent regions of local SAR discontinuity
where small modifications in chemical structures lead to large changes in po-
tency.2,4 In these regions high peaks correspond to activity cliffs. Activity cliffs
represent a prominent form of SAR discontinuity and are highly informative.
In most cases, a compound data set is represented as a “variable activity land-
scape”32 that is a combination of continuous and discontinuous SAR compo-
nents, as shown in Figure 1.4c. Such variable activity landscapes correspond to
the presence of SAR heterogeneity.4,32
10
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Figure 1.4: SAR characters. Shown are model 3D activity landscapes depicting (a.
continuous, b. discontinuous, c. heterogeneous) SAR characters, respectively. For landscape
generation, compounds are projected onto a 2D chemical reference space and activity is added
as the third dimension. Taken from [4].
The continuous SAR character is a prerequisite for virtual screening or lin-
ear QSAR applications. The discontinuous SARs, especially the activity cliffs,
are exploited in lead optimization campaigns, in order to improve compound
activity.4,30 Thus, the systematic description of the different SAR characteris-
tics, namely continuous, discontinuous and heterogeneous, helps to choose the
relevant application for analysis and/or prediction.
Numerical SAR Analysis
Complementing the activity landscape analysis, numerical functions that quan-
tify different SAR characteristics have also been developed.33,34 These functions
are based on pairwise calculations of structure and activity similarity for data
11
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set compounds. The SAR index (SARI)33 is a combination of the SAR continu-
ity and SAR discontinuity scores. The SAR continuity and discontinuity scores
quantify the continuous and discontinuous characters in compound data sets,
respectively, by taking the potency difference and similarity between compound
pairs into account. The SARI score is normalized and ranges from 0 to 1. Low,
intermediate and high scores correspond to discontinuous, heterogeneous and
continuous SAR characters, respectively.
The discontinuity score component of the SARI formalism can be used to
interpret the different SAR characteristics at a global level, i.e., for activity
classes and at a more local level, i.e., for a cluster of compounds within an
activity class.35 Furthermore, a local discontinuity score can also be calculated
to assess individual compound contributions to SAR discontinuity.35
Another numerical score reported by Guha et al.34 called the structure-
activity landscape index (SALI) quantifies pairs of compounds based on their
differences in activity divided by their distances in chemical space. It empha-
sizes pairs of structurally similar compounds with large potency differences and
is designed to detect activity cliffs in a data set.
Thus, numerical scores can be used to quantify and diagnose the different
SAR characters for compound data sets. These functions often complement the
landscape based SAR analysis. As graphical representations, the activity land-
scape models provide intuitive access to the SAR information of compound data
sets. However, with steadily growing numbers of active compounds, the activ-
ity landscapes become increasingly complex.36 This requires the design of other
novel graphical schemes to effectively extract SAR information. Many different
types of graphical schemes have been designed to assist in SAR analysis.
Graphical SAR Analysis
Molecular network representations have become increasingly popular for the
visualization of SAR characteristics of compound data sets. The structure-
activity similarity (SAS) maps37 are one of the earliest graph-based activity
landscape representations. In SAS maps, pairwise structural and activity sim-
ilarity is plotted along an xy-plane, such that each data point represents a
12
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pairwise compound comparison. Usually FPs are used as molecular representa-
tions and the similarity is accounted for by the Tc metric. Activity similarity
is represented as the logarithmic potency difference. Thus, a large difference
corresponds to low activity similarity and a small difference to high activity
similarity.
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HIGH 
HIGH 
Activity cliff 
region 
Figure 1.5: Structure-activity similarity maps. A schematic representation of an SAS
map is shown that depicts the structural and activity similarity for all compound pairs within
a data set in a scatter plot. Each compound pair is mapped to one of the four regions. The
activity cliff forming region can be identified at the bottom right section of the SAS map.
Adapted from [4].
The SAS map can be subdivided into four sections that capture different
SAR characteristics. A schematic illustration of the SAS map is presented in
Figure 1.5. The upper-left section contains pairs of compounds with high ac-
tivity and low structural similarity. This region can aid in the identification
of new active scaffolds with similar activity. The upper-right region contains
compound pairs with high structural and activity similarity, corresponding to
analogs with comparable potency. The lower-left section contains compound
pairs with low structural and activity similarity and does not contain any de-
sirable trait for further analysis. By contrast, compound pairs falling into the
13
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lower-right section have high structural and low activity similarity and repre-
sent the activity cliff region of an SAS map. These are highly informative for
further analysis.
More advanced molecular network representations such as network-like sim-
ilarity graphs (NSGs)35 help elucidate local SAR features in relation to the
global SAR features of the compound data. Here compounds are represented
as individual nodes. Edges are drawn between nodes to account for structural
similarity, if the compound pairs exceed a certain predefined Tc threshold.
Nodes are color-coded according to compound activity. A continuous color
spectrum is applied ranging from green (minimal potency in the data set) over
yellow (medium potency) to red (maximal potency). Nodes are also scaled in
size by the local per-compound discontinuity scores. Furthermore, cluster dis-
continuity scores are calculated to characterize the local SARs. A schematic
representation of an NSG is shown in Figure 1.6.
similarity > threshold 
similarity < threshold 
Edge 
Node size 
Potency 
high discontinuity 
low discontinuity 
min max 
Figure 1.6: Network-like similarity graphs. A schematic illustration of an NSG is
shown. Nodes correspond to compounds and edges between nodes represent compound pairs
that show structural similarity (Tc) greater than the defined threshold. The node sizes are
scaled according to the compound discontinuity scores. The node colors reflect compound
potencies as indicated by the color bar at the bottom. Adapted from [4].
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The node positions and edge lengths in NSGs are determined by a force-
directed graph layout algorithm38 that separates densely connected clusters
from each other. Thus, inter-cluster distances have no chemical meaning. The
clusters help to identify the most interesting local SAR regions. For example,
clusters of similarly colored and sized nodes highlight regions that are continu-
ous in nature. By contrast, clusters that show different colors and sizes indicate
the presence of local SAR discontinuity. Large red and green nodes connected
by edges indicate activity cliffs in the compound set.
NSGs have been primarily designed for the analyzes of lead optimization
sets, yet they have been proven to be equally intuitive and applicable for the
analysis of large screening sets.39
NSGs use whole-molecule similarity measures, which leads to additional
effort in interpreting structural changes. Representations that capture direct
substructure-based relationships overcome this limitation. These approaches
directly relate structural fragments with activity information. Substructure-
based relationships are captured by molecular scaffolds and MMPs.
A representation called the scaffold tree40 involves the systematic extraction
of molecular building blocks from sets of bioactive compounds. This is achieved
by first pruning all side chains and then subsequently removing rings from
molecular structures according to predefined chemical rules.40 This process is
carried out until a single ring structure remains. Each generated substructure
is organized hierarchically and is annotated with the activity information of
the compounds in which it is contained. A schematic illustration of the scaffold
tree is provided in Figure 1.7.
Given the rule-based decomposition of ring systems, the scaffold tree hierar-
chy contains scaffolds that are not contained in the data set compounds. These
virtual scaffolds can be utilized in compound design efforts. In a prospective
application of the scaffold tree data structure, novel (two- to four-ring) scaf-
folds for the enzyme 5-lipoxygenase and the nuclear receptor ERα have been
designed.41
MMP relationships have also been utilized to organize compounds and rep-
resent them graphically. One of the first representations that used MMPs was
the bipartite matching molecular series graph (BMMSG).42 BMMSGs not only
15
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Parent  
scaffold 1 
Compound 
Scaffold  
Parent  
scaffold 2 
--- 
--- 
--- 
--- 
--- 
--- 
Figure 1.7: Scaffold tree. A scaffold tree representation depicting the hierarchical frag-
mentation of model compounds is shown. The hypothetical activity distribution of com-
pounds represented by the corresponding scaffold is reported in bar charts. Substructures
removed in subsequent steps are highlighted in gray. Adapted from [30].
reveal global SAR trends in compound data set but also show local SAR pat-
terns in matching molecular series (MMS).42 An MMS constitutes of a set of
compounds that share the same core fragment and differ by substitutions at a
single site.
The concept of structurally analogous matching molecular series (A MMS)
was formulated on the basis of MMS.43 A MMS refers to multiple series with
structurally similar cores and overlapping substitution patterns. The SAR ma-
trix43 data structure organizes compound series as A MMS, such that the rows
represent structurally related cores and columns correspond to different sub-
stituents. Each cell represents a compound that is a combination of a core and
a substituent. The SARM is designed to systematically elucidate SAR patterns
in analog series. Furthermore, core-substituent combinations that do not repre-
16
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sent any data set compounds might arise, thereby extending the chemical space
to previously unexplored compounds. These “virtual compounds” are poten-
tial candidates for further exploration. Therefore, the SARM data structure
provides a link between descriptive SAR analysis and prospective compound
design.
Predictive Approaches
Activity landscapes are used to analyze SAR data sets for which activity values
have already been obtained from experiments. The numerical and graphical
SAR analysis schemes, described so far, characterize SAR patterns in a data
set but do not directly help in the activity prediction of novel compounds. The
activity landscape concept could be used to predict not just the activity of
novel compounds but also their local SAR environment, especially if they are
involved in the formation of activity cliffs.
Activity cliffs represent the extreme form of SAR discontinuity and tradi-
tional QSAR methods are unlikely to predict very different activities for two
structurally similar molecules. So far, the activity cliff analysis has been descrip-
tive in nature. Applications have attempted to mine and analyze activity cliffs
from public databases24,44 or directly identify structural modifications that lead
to their formation.45 Recently, studies have begun to directly predict whether
novel molecules would form activity cliffs using the activity landscape paradigm.
One study attempted to identify activity cliffs by predicting SALI values for
pairs of molecules using random forest46 models.47 Predicted SALI value for
a novel compound is an indicator of its ability to form an activity cliff when
paired with other molecules in the data set. Another study utilized the MMP
representation to classify molecule pairs as activity cliff forming and activity
cliff non-forming using support vector machine (SVM)48 approach.49 The study
attempted to identify structural features among compounds sharing a specific
activity that are responsible for high and low potency and thus, ultimately, for
the formation of activity cliffs. Another study utilized the emerging chemical
patterns (ECP)50 approach to identify distinguishable structural and potency
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characteristics from compounds forming activity cliffs.51 These patterns were
used for the prediction of unknown activity cliff forming compounds.
Prediction of a novel compound’s local SAR environment, using the ECP
method, has also been attempted.52 Here, per-compound SARI discontinuity
scores were calculated and patterns that distinguished compounds with low,
intermediate and high discontinuity scores were employed for classifying com-
pounds that mapped to low, intermediate and highly discontinuous SAR re-
gions, respectively.
These methods have attempted to utilize SAR characteristics derived from
activity landscape models for prediction purpose. Thereby the role of activity
landscape models was extended from descriptive to predictive applications. The
predictive approaches complementing descriptive activity landscape methods
can help in prospective compound design.
Multi-Target Activity Spaces
Currently it is widely recognized that many pharmaceutically relevant com-
pounds and drugs elicit therapeutic effects by interacting with multiple tar-
gets.53,54 The presence of specific interactions of a compound with multiple
targets is referred to as compound promiscuity and provides the basis for
polypharmacological effects.55,56 The analysis of compound promiscuity is useful
for chemogenomics applications.
Public compound repositories57 represent the largest source of publicly avail-
able chemogenomics data. The degree of compound promiscuity observed is
dependent on the type of activity measurements that are considered.58 A study
analyzing the growth of compound activity data in the ChEMBL59 repository
found out that compound promiscuity rates involving distantly related or unre-
lated targets increase when assay-dependent (IC50) measurements are utilized.
58
Systematic data mining efforts and compound and/or target network repre-
sentations have been deployed to understand compound promiscuity in different
contexts.56 Systematic analyses at the level of molecular scaffolds have identi-
fied scaffolds that are selective for closely related targets and scaffolds that are
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promiscuously active across multiple target families.60,61 Network representa-
tions were utilized to study scaffold-target family relationships of promiscuous
scaffolds. A bipartite network with different types of nodes representing scaf-
folds and target families was generated. Edges were drawn between the two
node types if the scaffold was active against the target family. The network
helped in the identification of promiscuity patterns among topologically equiv-
alent scaffolds active against different target families.61
In another study, MMP formalism has been utilized to explore structure-
promiscuity relationships in a compound profiling data set using 100 sequentially-
unrelated proteins.62,63 126 compound pairs where small structural modifica-
tions led to large-magnitude change in promiscuity, i.e., promiscuity cliffs were
detected. A network representation, as shown in Figure 1.8, was utilized to indi-
cate compound pairs that formed promiscuity cliffs. Here, each node represents
a compound and is color-coded according to the number of target annotations
by applying a continuous color spectrum from black for inactive compounds
to white for highly promiscuous compounds. Nodes are connected by edges if
the compounds form promiscuity cliffs. Two representative promiscuity cliffs
are also shown in Figure 1.8. The presence of promiscuity cliffs suggested that
promiscuity is not an inherent feature of molecular scaffolds but can be induced
by small chemical substitutions.63
Data mining and especially visualization tasks are complicated for chemoge-
nomics data given their multi-target nature and the substantially varying de-
grees of compound promiscuity.65 No single data mining effort or network rep-
resentation is able to capture its complexity. Hence, a combination of novel
intuitive mining and graphical methods need to be deployed for the same.65
Thesis Outline
The primary objective of this dissertation is to introduce novel methods that
facilitate SAR exploration and activity predictions using the activity landscape
framework. The studies guide compound design efforts in pharmaceutical re-
search.
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Figure 1.8: Network representation for promiscuity cliffs. 126 promiscuity cliffs are
organized in a network representation (left). Nodes represent compounds and edges indicate
promiscuity cliffs. Nodes are color-coded according to the number of target annotations
using a continuous color spectrum from black (0 targets; inactive) to white (97 targets; most
promiscuous). Two representative promiscuity cliffs are shown on the right. The number of
targets each compound is active against is reported. Substructural changes are highlighted
in red. Taken from [64].
This dissertation consists of six studies that are organized as individual
chapters:
• In Chapter 2, a newly designed landscape model that utilizes the canon-
ical scaffold and skeleton representation to organize compound sets in
a consistent and hierarchical manner is reported. SAR information can
be intuitively extracted from the model. Exemplary analyses of different
compound data sets reveal how global and local SAR patterns can be
identified.
• The SAR matrix (SARM) methodology based on the MMP formalism is
designed to systematically extract structurally related compound series
20
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from compound data sets and organize these in matrices.4 In Chapter 3,
methodological extensions have been introduced for the SARM method.
These second generation SARMs are useful for applications in medicinal
chemistry and chemogenomics. This study summarizes the methodologi-
cal advancements and Chapters 4 and 5 report them in detail.
• In Chapter 4, a computational and graphical framework based on the
SAR matrix method for the analysis of multi-target activity spaces and
compound promiscuity patterns is introduced.
• The virtual compounds emerging in the SAR matrix data structure are
potential candidates for further exploration. In Chapter 5, a novel QSAR-
based approach utilizing local chemical neighborhood information for vir-
tual compound activity prediction from SAR matrices is reported.
• The prediction method described in Chapter 5 can only be utilized for
hit-to-lead or lead optimization sets, where explicit potency values are
available. Therefore, a conditional probability-based prediction approach
using SAR matrices has been developed and evaluated in Chapter 6. This
method is applicable for screening sets and is useful for hit expansion.
• Chapter 7 reports the results of the first prospective application of the
SARM-derived probability approach described in Chapter 6.
At the end, the key aspects and results of the work presented in this dissertation
are summarized in Chapter 8.
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Chapter 2
Introducing the LASSO Graph
for Compound Data Set
Representation and
Structure-Activity Relationship
Analysis
Introduction
Many different activity landscape representations that facilitate the understand-
ing of SAR characteristics of bioactive compounds have been developed.1 Crit-
ical parameters in the design of activity landscape models are the choice of
a molecular representation and a similarity metric. Graphical representations
using different parameters offer opportunities to identify distinct SAR patterns
in compound data sets.
In this study, a novel activity landscape representation is introduced in
which compounds are organized following a canonical scaffold-skeleton struc-
tural hierarchy. Hierarchical and substructural relationships between com-
pounds are captured in a novel graphical design. Compound activity data is
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integrated to reveal informative SAR patterns. Exemplary applications demon-
strate the prominent SAR features of this novel representation.
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ABSTRACT: A graphical method is introduced for compound
data mining and structure−activity relationship (SAR) data
analysis that is based upon a canonical structural organization
scheme and captures a compound−scaffold−skeleton hierarchy.
The graph representation has a constant layout, integrates
compound activity data, and provides direct access to SAR
information. Characteristic SAR patterns that emerge from the
graph are easily identified. The molecular hierarchy enables
“forward−backward” analysis of compound data and reveals
both global and local SAR patterns. For example, in
heterogeneous data sets, compound series are immediately
identified that convey interpretable SAR information in isolation
or in the structural context of related series, which often define
SAR pathways through data sets.
■ INTRODUCTION
For the extraction of SAR information from large compound
data sets, visualization techniques that view SAR features from
different angles have become increasingly popular in recent
years.1,2 For instance, graphical methods have been introduced
to globally represent data sets3−6 or generate compound-
centric7,8 and series-centric views.9−11 Global graphical analysis
approaches include molecular-network-type representations3,4
or diagrams that compare molecular similarity and activity
similarity of compounds in a pairwise manner.5,6 In these plots,
molecular similarity is generally assessed by calculating
Tanimoto similarity of test compounds using various
descriptors, in particular, fingerprints.5,6 In SAR networks,
similarity relationships (edges) might be established in an
analogous manner3 or by accounting for substructure relation-
ships between active compounds.4 In addition, local SAR
representations might either monitor the structural neighbor-
hood of active compounds7,8 or concentrate on individual
analogue series.9−11 The latter methods include graphical
extensions of conventional R-group tables9 as well as network-
like representations.10,11 In such networks, analogues might be
organized by substituent sites and site combinations9 or on the
basis of systematically determined substructure relationships.10
In addition to these global or local compound data set
representations, molecular scaffolds originating from active
compounds have also been graphically organized in different
ways.12 For example, for SAR monitoring, Scaffold Explorer13
has been introduced, an interactive editor that links scaffold-like
structures to an R-group table. Graphs containing these
structures can be interactively built, modified, and annotated
with SAR information. The tool is designed to aid medicinal
chemists in processing R-group tables containing different core
structures. Going beyond interactive analysis, a rule-based
organization scheme for scaffolds is provided by the Scaffold
Tree data structure.14 Following this approach, scaffolds are
decomposed along pathways by iteratively removing rings from
them according to a set of predefined chemical preference rules
until single-ring scaffolds remain. Given this rule-based
decomposition scheme, scaffolds might be obtained along the
tree that are not contained in the original data set compounds,
which is a key feature of this approach. These “virtual” scaffolds
can then be used for activity prediction, considering the activity
of neighboring “real” scaffolds. Compound activity predictions
on the basis of virtual scaffolds have been further exploited in
an extension of the Scaffold Tree approach termed Scaffold
Hunter.15
In principal, a scaffold-based representation of a compound
data set can be further extended specifically for SAR analysis by
following a hierarchical structural organization scheme from
active compounds over conventional molecular scaffolds16 to
cyclic skeletons (CSKs),17 which further abstract from scaffolds
by omitting heteroatom and bond order information. This
hierarchical organization scheme has previously been applied by
us to systematically map target annotations to different
compound classes.12 A key aspect of this approach is that
each CSK represents a family of topologically equivalent
scaffolds. Hence, scaffolds can be organized according to their
topology and further distinguished on the basis of chemical
criteria.
In order to utilize this concept for SAR analysis, we have
designed a canonical data structure that exploits structural
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compound−scaffold−skeleton hierarchy in a “forward−back-
ward” manner. This is accomplished by first extracting scaffolds
and CSKs from active compounds and then organizing the data
set in different layers defined by CSKs containing stepwise
increasing numbers of rings. These layers capture the associated
scaffold and compound information in a graphically intuitive
Figure 1. Graph generation. In (a) and (b), the generation of the LASSO graph is illustrated, as described in the text. In the exemplary data set,
compounds are labeled with their potency (Ki) values. Scaffolds are colored red. In (c), substructure relationships between CSKs across different
graph layers are depicted. In each pair of CSKs connected by an edge, the parental CSK is colored red. In addition, on the left, the prioritized
assignment of CSK relationships is illustrated.
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manner. We term this data structure the “layered skeleton−
scaffold organization” or LASSO graph (because its layout also
reminds us of “roping” SAR information). On the basis of our
evaluation, we find the LASSO graph structure to be very well
suited for compound data set representation and the
exploration of both global and local SAR features. For example,
analogue series are immediately identified that convey SAR
information in isolation or in the structural context of related
series. Furthermore, structural pathways through data sets are
obtained that also reveal SAR information. The design of the
LASSO graph and exemplary applications are reported herein.
■ METHODS AND MATERIALS
Scaffold Generation. Scaffolds consisting of ring systems
and linkers between them were obtained by removal of all R-
groups from compounds following Bemis and Murcko scaffold
definition.16 However, in a departure from this conventional
definition, exocyclic double bonds attached to ring atoms were
not removed but retained. Hence, substituents with exocyclic
Figure 2. Graph representation. Prototypic LASSO graphs are shown. (a) Melatonin receptor 1A antagonists. (b) Nociceptin receptor antagonists.
In (c), the rectangular subgraph on layer 5 on the left is enlarged and for each of six selected scaffolds (red) representing 3−25 compounds (reported
in parentheses) the least and most potent analogues are shown. These topologically equivalent scaffolds represent analogue series with different
potency progression.
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double bonds were not considered conventional R-groups. In
addition, this modification led to the generation of further
diversified scaffold sets. Scaffolds in LASSO graphs also contain
stereocenter information. Scaffolds were further transformed
into CSKs17 by changing all heteroatoms to carbons and setting
all bond orders to one. Importantly, scaffolds and CSKs are
separately accounted for in LASSO graphs as a part of
compound−scaffold−skeleton hierarchies.
Graph Design. The organization of the graph is based upon
systematically derived substructure relationships between CSKs
that are present in a data set. Scaffolds and compounds
associated with each CSK are incorporated into the graph
representation using different design elements, as discussed in
the following. Figure 1a and Figure 1b illustrate the design
elements of the graph.
Substructure Relationships. CSKs are organized by the
number of rings they contain. Each number of rings (from 1 to
n) corresponds to a separate layer in the graph. If a CSK
contains a condensed ring system, each participating ring is
considered a separate entity (and counted separately). Then a
parent−child relationship is defined between two CSKs if a
CSK at a given layer is completely contained in the structure of
another CSK at a higher layer. This might be the next higher
layer or a subsequent one, i.e., a parent−child relationship
might involve CSKs that differ by more than one ring. Figure
1b illustrates these substructure relationship assignments. If a
CSK has multiple possible parents, the relationship with a
parent is prioritized that contains fewer linker atoms between
rings, as illustrated in Figure 1c.
Layout. The resulting layers are captured in a hierarchical
graph structure. A radial graph layout is used for visualization.
Each level of the structural hierarchy is represented by a
concentric circle onto which CSKs with the corresponding
number of rings are placed as nodes. Therefore, the structural
complexity of CSKs increases from the inner to outer layers.
This layout enables the simultaneous presentation of multiple
subgraphs with different roots.
Annotation and Visualization. In Figure 1a, a model
compound set is shown and potency-based coloring is
illustrated. The compound potency range within a data set is
accounted for using a continuous color spectrum from green
(lowest) to red (highest potency in the data set). In Figure 1b,
CSKs are represented as rectangular nodes. Edges between two
CSKs define a parent−child substructure relationship. In
addition, individual scaffolds are depicted as circular nodes.
Scaffolds represented by a given CSK are embedded within the
rectangular CSK node. Thus, by definition, a CSK node must
contain at least one scaffold node. Furthermore, scaffolds are
color-coded based on the potency of the compounds they
represent. If a scaffold represents multiple compounds, it is
divided into an equally sliced pie chart where each slice
represents an individual compound colored by its potency.
Implementation. All routines required to generate
scaffolds and CSKs were implemented in Java using the
OpenEye chemistry toolkit.18 The graph structure was
generated using the Java package JUNG.19
Data Sets. For graph evaluation and SAR analysis, different
compound data sets were extracted from ChEMBL.20 The data
sets can be obtained via the following URL: http://www.limes.
uni-bonn.de/forschung/abteilungen/Bajorath/labwebsite
(please, see the “downloads” section).
■ RESULTS AND DISCUSSION
Characteristic Features of the LASSO Method. By
design, LASSO is an SAR data mining method. As such, it does
not directly provide suggestions for new analogues on the basis
of graphical analysis; i.e., it is not a predictive approach. The
methodology is devised to identify the most interesting
compound subsets or series in large and structurally
heterogeneous data sets, which is a particular strength of the
underlying hierarchical molecular organization. Once com-
pound series yielding interpretable SAR information have been
extracted from such data sets, design of new compounds can be
attempted in subsequent steps. Utilizing a hierarchical
organization scheme for data mining and analysis has additional
implications. For example, molecular hierarchies do not encode
synthetic routes to generate compounds. However, they
establish substructure and topological relationships between
compound series that could not be established on the basis of
synthetic criteria or by utilizing R-group tables or related
representations. Compared to other hierarchical scaffold
organizations such as scaffold trees, the most distinguishing
features of the LASSO approach include the addition of
topological relationships conveyed in the graphs and the
“forward−backward” analysis capacity of scaffold and corre-
sponding compound information, which provides an intuitive
access to SAR patterns. An important feature of LASSO is that
SAR information is represented in the form of compound−
scaffold−skeleton sequences (rather than only using scaffolds),
which reflects SAR information at different structural levels and
enables a direct comparison of SAR patterns in different
compound series.
Prototypic LASSO Graphs. In Figure 2, exemplary LASSO
graphs are shown to illustrate general topological character-
istics. The graph is arranged in concentric layers according to
the presence of increasing numbers of rings in CSKs. Hence,
layer 1 always corresponds to one or more CSKs containing a
single ring, which might or might not be present in a given data
set. If no single-ring CSK is available, layer 1 is empty. From
layer to layer, the number of rings contained in CSKs increases
exactly by 1. CSKs connected by edges form pathways across
different layers, depending on their substructure relationships.
The more substructure relationships are present, the more
densely connected the graph will be. Depending on these
relationships, CSK pathways might not involve each layer. In
addition, multiple pathways might originate from the same or
different layers (in this case, the JUNG implementation places
pathways on layers by balancing radial distances between
them). Importantly, any data set compound will appear in the
graph, regardless of whether the corresponding CSK is involved
in substructure relationships or not. The position of a
compound in the graph is determined by the number of
rings its CSK contains.
In Figure 2a and Figure 2b, LASSO graphs are shown for sets
of antagonists of the melatonin receptor 1A and nociceptin
receptor, respectively. Both graphs consist of six layers (i.e.,
CSKs contain a maximum of six rings), but their topology
differs. The melatonin receptor 1A antagonist set in Figure 2a is
structurally more homogeneous than the nociceptin receptor
antagonist set in Figure 2b that yields a number of singletons
and disjoint pathways. Furthermore, the graph of the nociceptin
receptor antagonist set has no CSK at the first layer and
contains only one CSK with two rings. In Figure 2c, the largest
rectangular node of the nociceptin receptor antagonist graph is
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displayed in detail. This subgraph contains analogue series
represented by a total of 21 topologically equivalent scaffolds.
Exemplary analogues are shown. As can be seen, these related
analogue series display rather different potency progression.
Hence, this node reveals a high degree of SAR heterogeneity
and the compound series it contains are a primary focal point of
SAR analysis.
SAR Patterns. As illustrated in Figure 1, compounds are
consistently represented in the LASSO graph as a part of the
skeleton−scaffold−compound hierarchy. This means that each
compound is contained in a rectangular CSK node and a
circular scaffold node. The presence of multiple compounds
sharing the same scaffold gives rise to a color-coded pie chart
representation of the scaffold node. By definition, these
compounds form an analogue series. In the LASSO graph,
characteristic patterns emerge that contain this basic design
element and reflect available SAR information. These character-
istic graph patterns are displayed in Figure 3. Pattern 1, the
simplest one, represents a series of analogues with steady
potency progression. Such a series typically contains interpret-
able SAR information. Pattern 2 mirrors the presence of
topologically equivalent analogue series with varying potency
distribution. In this case, SAR features can be compared across
different yet related scaffolds and series. Pattern 3 is a
characteristic horizontal pattern emerging from a LASSO
graph. Here, individual compounds or series share a particular
given CSK as the largest common substructure and are only
distinguished by the presence and/or position of an individual
ring. In this example, potency progression is observed from the
right to the left. The potency distribution among such series
might be indicative of preferred scaffolds. Furthermore, pattern
4 illustrates a characteristic vertical pattern, resulting from the
stepwise addition of a single ring to a CSK. In this case, steady
potency progression is also observed along the path. If
horizontal or vertical patterns contain compounds or series
with different potency distribution, they are arranged in the
order of increasing potency, which aids in the identification of
SAR-sensitive series and high-priority candidates for further
exploration.
Graph Analysis. In the following, two examples are
discussed to further illustrate the use of LASSO graphs for
SAR exploration.
Serotonin 7 Receptor Antagonists. In Figure 4a, the
LASSO graph of a set of 246 antagonists of the serotonin 7
receptor is shown. These compounds yield 119 distinct
scaffolds and 76 CSKs. The LASSO graph is characterized by
the presence of seven layers and densely connected pathways
that originate from the same CSK containing a single ring,
hence revealing many substructure relationships. In the graph,
three characteristic patterns are labeled (according to the
numbering scheme in Figure 3). In Figure 4b, structures
forming patterns 1 and 2 are shown in detail. In this and all
following illustrations of graph patterns, CSKs, corresponding
scaffolds, and (representative) compounds comprising a pattern
are shown. Pattern 1 in Figure 4b is formed by 24 analogues
spanning a large potency range, which represents a typical SAR
hotspot. In addition, pattern 2 is formed by the bipenyl scaffold
and three closely related scaffolds. However, similar analogues
represented by these scaffolds have significant differences in
potency, maximally of more than 3 orders of magnitude. Thus,
as revealed by the pattern, a substantial amount of SAR
information is available for these biphenyl derivatives. In Figure
4c, the third pattern marked in Figure 4a is shown in detail,
which represents a typical horizontal pattern. Five scaffolds and
the exemplary compounds they represent are displayed (in
several cases, the compounds already represent scaffolds). In
this case, the pattern is formed by only a few analogues with
steady potency progression of approximately 2 orders of
magnitude.
Bradykinin B1 Receptor Antagonists. In Figure 5a, the
LASSO graph of 348 antagonists of the bradykinin B1 receptor
is shown that yield 132 scaffolds and 68 CSKs. The LASSO
graph of this compound set also spans seven layers. Although
the numbers of CSKs and scaffolds are comparable to the
serotonin receptor antagonist example, in this case, the edge
density in the LASSO graph is low and a number of singletons
are observed, revealing the presence of only limited CSK
substructure relationships. Nevertheless, the graph also contains
Figure 3. Graph patterns. Shown are four characteristic graph elements or patterns that convey SAR information, as described in the text.
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a number of structural pathways and obvious patterns, three of
which are marked in Figure 5a (and again numbered according
to Figure 3). In Figure 5b, pattern 1 is highlighted, a series of
analogues with steady potency progression spanning nearly 4
orders of magnitude, one of the SAR hotspots in this data set.
From these analogues, it becomes immediately apparent that
the introduction of a nitrile group at the cyclohexane ring
significantly increases compound potency. Furthermore, single
halogen substiturents at the benzene ring are preferred at the
ortho and meta positions. However, the largest increase in
potency is observed when a bulky trifluoromethyl group is
present at the ortho-position. In addition, Figure 5c shows
structures that participate in the formation of pattern 2
involving a total of 10 topologically equivalent scaffolds (each
containing two pairs of condensed rings and two additional
single rings). Among these are chemically very similar scaffolds
representing compounds that are only distinguished by one or
two ring substitutions and/or stereochemistry at a single
stereocenter. However, these modifications cause potency
differences of 2−4 orders of magnitude. Hence, this pattern
Figure 4. LASSO graph of serotonin 7 receptor antagonists. In (a), the LASSO graph of the compound data set is shown and characteristic patterns
are marked and numbered according to Figure 3. In (b) and (c), these patterns and corresponding structures are depicted. For each CSK, the
numbers of corresponding scaffolds and compounds are reported in parentheses (in blue and red, respectively). For each pattern, CSKs, scaffolds
(on a light blue background), and representative compounds (light gray background) are shown (labeled with their pKi values). For pattern 1, R-
groups in compounds are colored red. For pattern 3, rings that distinguish CSKs are also colored red.
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identifies a highly SAR-informative compound subset. More-
over, in Figure 5d, pattern 4 is analyzed, a characteristic vertical
pattern formed by a disjoint structural pathway from layer 4 to
layer 6 in the graph. Here, the addition of two single rings in
subsequent steps leads to significant progression in potency.
The two scaffolds represented by the terminal CSK in layer 6
yield highly potent compounds. A comparison of two
representative highly potent compounds (with pKi values of
9.8 and 10.0, respectively; bottom of Figure 5d) containing a
terminal piperidyl ring with a compound represented by the
intermediate scaffold in layer 5 (pKi of 9.3; on the right in
Figure 5d) is particularly interesting. The latter compound is
much more potent than its closely related analogues and also
contains an aliphatic piperidine mimic at the corresponding
substitution site. Thus, this comparison clearly implicates the
piperidine substituent as an SAR determinant within this series.
It also illustrates that vertical graph patterns can reveal detailed
SAR information.
■ CONCLUSIONS
Herein we have introduced a new and intuitive graphical data
mining method for the structural organization and representa-
tion of compound sets and the exploration of SAR information.
The LASSO graph globally organizes compound sets according
to a well-defined structural hierarchy, integrates compound
activity data, and reveals signature patterns that capture SAR
information. Conceptually, the LASSO graph is related to the
Scaffold Tree data structure. However, different from the
Scaffold Tree and its extensions, the LASSO graph is not
designed for scaffold decomposition or generation of virtual
scaffolds. Moreover, it is focused on a compound data set rather
than scaffold representation. LASSO graphs also take an
additional structural criterion into account, the topological
Figure 5. LASSO graph of bradykinin B1 receptor antagonists In (a), the LASSO graph of the compound data set is shown and characteristic
patterns are marked and numbered according to Figure 3. In (b), (c), and (d), these patterns and corresponding structures are depicted. The
presentation is according to Figure 4. In the analogues corresponding to pattern 1, a conserved substituent at the pyridine moiety is shown in dark
gray and R-groups that reveal SAR information are shown in red and blue. For pattern 4, rings added at each layer are colored red.
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equivalence of scaffolds, which is assessed by considering cyclic
skeletons. Characteristic features of the LASSO graph include
its constant reference frame for the representation of
structurally homogeneous or heterogeneous compound sets
and its signature patterns that identify SAR-informative
compound subsets. A special feature of LASSO that sets it
apart from other scaffold representations is the presence of
compound−scaffold−skeleton sequences that capture substruc-
ture and topological features of active compounds at different
levels and enable “forward−backward” SAR exploration. The
data structure emphasizes both global and local structural and
SAR features. As such, the LASSO graph further extends the
current spectrum of graphical SAR analysis tools. Exemplary
applications suggest that ease of interpretation is a particular
attractive aspect of LASSO graph analysis.
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CHAPTER 2: SUMMARY
Summary
The LASSO graph is a novel representation that provides a bird’s eye view
of SARs in compound data. It utilizes hierarchical molecular frameworks to
organize compound sets for the exploration of SAR information. The compact
graphical layout reveals both global and local SAR patterns. Signature patterns
that identify SAR-informative compound subsets can be easily identified from
the compact graphical layout. Additionally, the graphical topology enables
the recognition of structurally homogeneous and heterogeneous compound data
sets. My contribution to this study has been the implementation of the LASSO
graph and the analysis of different compound data sets using the graph.
The LASSO graph representation is restricted to descriptive SAR analysis.
It does not directly provide novel compound design suggestions and activity
predictions. The SAR matrix data structure organizes SAR-informative com-
pound series from large data sets and reports several virtual compounds for
optimization. This data structure has been further extended to help bridge the
gap between data-driven SAR analysis, compound design, and activity predic-
tions and study compound series in multi-target activity spaces. In Chapter 3,
the SAR matrix approach and its extensions are presented.
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Chapter 3
Second Generation SAR
Matrices
Introduction
Activity landscapes are indispensable tools for SAR analysis, however, a steady
increase in the size of compound data is making SAR analysis extremely chal-
lenging.2 It is essential to develop computational methods that can handle in-
creasing complexity of data. The tools should provide intuitive approaches for
seeking SAR information and compound design.
The SAR matrix (SARM)3 method provides an opportunity for combin-
ing large-scale SAR analysis and prospective compound design. In SARMs,
compounds are organized as structurally related series in a format reminis-
cent of R-group tables. A dual-step MMP fragmentation approach is used
to generate these series. SARMs are represented in a matrix format where
structurally-related cores are represented in rows and substituents are repre-
sented in columns. Each cell represents a compound as a combination of the
core and a substituent. A salient feature of the SARMs is the presence of virtual
compounds (VCs) that populate chemical space around structurally related se-
ries. These VCs represent unexplored combinations of cores and substituents
and are potential candidates for further exploration. SARMs are useful for an-
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alyzing hit-to-lead and lead optimization sets in order to identify and optimize
potential compound series.
In a collaboration with Pfizer, a focused lead optimization set of approxi-
mately 10,000 structurally related kinase inhibitors was analyzed using SARMs.
The resulting VCs served as potential candidates to synthesize and test. How-
ever, prioritization of a few candidates was difficult from a large number of
matrices. This triggered the development of a novel approach to predict VC
potency using the SARMs. This advancement helps prioritize the VCs and
enhances the utility of SARMs for medicinal chemistry applications.
The SARM method is also utilized to study compound series in multi-
activity spaces. The purpose here is not SAR analysis but systematic ex-
ploration of compound promiscuity patterns in structurally related analogs.
These matrices, referred to as compound series matrices (CSMs), offer sugges-
tions for the design of compounds with multi-target activities and are useful
for chemogenomics applications.
In this Chapter, the SAR matrix data structure and its novel methodological
extensions are discussed.
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Introduction
Steadily growing numbers of active compounds provide a critically 
important knowledge base for medicinal chemistry but also chal-
lenge Structure-Activity Relationship (SAR) analysis1. For important 
therapeutic targets, compound activity landscapes become increas-
ingly complex2 and difficult to analyze. Increasing volumes and 
complexity of compound activity data require the development of 
computational approaches to effectively extract SAR information 
from heterogeneous sources1. In addition, it is essential to make this 
information available in an intuitive form that can be appreciated in 
the practice of medicinal chemistry and utilized in compound design. 
Therefore, a number of SAR visualization methods and graphical 
analysis tools have been developed in recent years2,3 to view SAR 
characteristics of entire data sets or extract SAR information from 
compound activity data. Regardless of their algorithmic founda-
tions and design specifics, many (but not all) graphical analysis 
methods have in common that they provide a bird’s eye view of 
SAR information in compound data sets and depart from the single-
series focus that has traditionally governed medicinal chemistry 
efforts. However, multi-facetted SAR information obtained from 
heterogeneous compound sources must ultimately again be utilized 
to advance individual compound series, which is a challenging task.
The Structure-Activity Relationship Matrix (SARM) approach has 
originally been designed to extract and organize SAR-informative 
compound series from large data sets4 and has been further extended 
to help bridge the gap between data-driven SAR analysis, compound 
design, and activity predictions5 and study compound series in multi-
target activity spaces6. Here, we present the SARM approach and its 
extensions in context and introduce new features and applications.
Methods
Compound structure analysis and organization
The original design idea underlying the SARM approach was to 
systematically extract compound series with well-defined structural 
relationships from data sets and organize them in a matrix format4. 
To convey SAR information, matrix cells representing data set com-
pounds are color-coded according to compound potency. The meth-
odological basis for compound series identification and organization 
was provided by the matched molecular pair (MMP) concept7. An 
MMP is defined as a pair of compounds that differ only at a single 
site7. Compounds in MMPs can be interconverted by the exchange 
of a substructure, termed a chemical transformation8. In order to 
generate MMPs on a large scale, compounds must be systemati-
cally fragmented. The algorithm by Hussain and Rea8 (which we 
re-implemented and further modified in-house) provides an elegant 
and computationally efficient solution to this task by subjecting 
compounds to systematic deletion of individual exocyclic single 
bonds (single-cut) or simultaneous deletion of two (dual-cut) and 
three (triple-cut) exocyclic single bonds. The resulting fragments 
are then stored in an index table as keys (core structures) and smaller 
values (substituents)8.
The most important aspect of SARM design has been the applica-
tion of dual fragmentation scheme leading to MMP generation at 
two levels4, as outlined in Figure 1. In the first step, MMPs are gen-
erated from data set compounds yielding “compound MMPs”. In the 
second step, core fragments from compound MMPs are again sub-
jected to fragmentation leading to the generation of “core MMPs”. 
As a consequence, this hierarchical two-step fragmentation scheme 
identifies all compound subsets that have structurally analogous 
cores, i.e., core structures that are only distinguished by a struc-
tural modification at a single site. Each subset represents a so-called 
“structurally analogous matching molecular series” (A_MMS)4. 
Thus, each A_MMS represents a set of compound series with struc-
turally analogous cores. Individual compounds and/or subsets of 
compounds can belong to multiple A_MMS, hence providing a 
high-level structural organization of a compound collection that 
captures all possible (MMP-based) substructure relationships.
SAR matrix design
Each A_MMS is represented in an individual SARM, as illustrated 
in Figure 1. The SARM is filled with structurally analogous cores 
resulting from core MMPs (second fragmentation step) and the 
corresponding substituents obtained from compound MMPs (first 
fragmentation step). Single-, dual-, and triple-cut matrices are sepa-
rately generated (vide supra). Each cell in a SARM represents a 
unique compound, i.e., a unique combination of a key and value 
fragment. Each row contains an individual analog series, i.e., com-
pounds sharing the same core. Each column contains compounds 
from different series that share the same substituent (single-cut) or 
substituent combination (dual- or triple-cuts). The series forming a 
SARM typically contain different sets of substituents, giving rise 
to “real” compounds (filled cells) and “virtual” compounds (VC; 
      Amendments from Version 1
We thank all reviewers for their comments. Compound sets 
used to generate the matrices discussed in the paper are made 
available as a part of the revision (via ZENODO, please see ref. 
16). Readers might also be interested in other publicly available 
data sets and software tools originating from our laboratory 
[Hu and Bajorath, F1000Research 2014, 3:69 (doi: 10.12688/
f1000research.3979); Hu et al. F1000Research 2014, 3:36 (doi: 
10.12688/f1000research.3-36.v2]. SARM software is currently not 
included but the method can be readily implemented on the basis 
of the information provided.
In the revision, we have expanded the method description (point 
3 of the second review) and made corrections (including numbers 
in Figure 7) and stylistic changes (points 4 and 6). In addition, 
Figure 1 and Figure 5 have been updated with chemically intuitive 
compound series. The remaining questions from the second 
review are answered below (but the answers have not been added 
to the revision, given the more general nature of these questions): 
1. Yes. If such rings are connected via exocyclic bonds to 
the remaining part of a molecule, the bonds are regularly 
fragmented and MMPs might be generated.
2. The concept of a Matching Molecular Series was introduced 
in Wawer and Bajorath, J Med Chem 2011, 54:2944–2951 
(doi: 10.1021/jm200026b) and has recently been utilized 
by O’Boyle et al., J Med Chem 2014, 57:2704–2413 (doi: 
10.1021/jm500022q), in the latter case termed Matched 
Molecular Series.
6. Yes. CSMs can be used to study secondary drug targets 
and adverse drug reactions. In this context, please also see 
an MMP application by Hu et al. AAPS J 2014, in press (doi: 
10.1208/s12248-014-9621-8). 
See referee reports
REVISED
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Figure 1. SAR matrix generation. Three model series with three compounds each (A–C, D–F, and G–I) are shown with pKi values (red). In 
the first step, all compounds are fragmented at a single bond (purple dotted line) producing compound MMPs that yield a common core (key) 
and a compound specific substituents (values). In the second step, the cores resulting from the first step are further fragmented to obtain core 
MMPs. The SARM is then generated by combining series with structurally analogous cores that represent individual rows. In addition, columns 
represent substituents. In each cell, the combination of a core and a substituent defines a unique compound. Compounds present in the 
data set are indicated by filled cells that are color-coded according to potency using a continuous spectrum from red (low potency) over yellow 
to green (high). In addition, empty cells indicate virtual compounds. Substructures distinguishing the core fragments are highlighted in red.
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empty cells). As also illustrated in Figure 1, a color spectrum is 
applied to represent the potency (or ligand efficiency) values of real 
compounds. Importantly, SARMs resemble standard R-group tables 
used in medicinal chemistry, although their design and informa-
tion content is much more complex and comprehensive. Standard 
R-group tables typically only contain an individual core structure 
of a single series, all substituents, and associated potency values. 
However, because SARMs resemble R-group tables, they are read-
ily accessible to medicinal chemists who can inspect individual 
compounds and their relationships to others.
SAR patterns
In SARMs, different types of SAR patterns become readily appar-
ent. This is illustrated in Figure 2 that shows exemplary SARMs 
Figure 2. SAR patterns in matrices. In (a), a SARM capturing 16 ligands of the histamine H4 receptor is shown. Cells containing analogs with 
preferred cores yielding potent compounds are framed in blue. Substructures distinguishing the core fragments are highlighted in red. The 
pKi value range for the 16 ligands is displayed. In (b), a subset of a double-cut SARM is shown that contains series of carbonic anhydrase I 
inhibitors and an exemplary SAR transfer event.
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revealing characteristic patterns (for representation purposes, only 
small matrices are shown; vide infra). For example, the SARM in 
Figure 2a identifies two preferred core structures that consistently 
produce potent compounds. Furthermore, the SARM in Figure 2b 
reveals an SAR transfer event, i.e., the presence of two compound 
series with related yet distinct core structures that contain pairwise 
corresponding analogs with similar potency progression. Other 
SAR patterns that can frequently be detected include, for example, 
preferred R-groups (or R-group combinations) in related compound 
series or regions of distinct SAR continuity or discontinuity. Con-
tinuous SAR regions are characterized by the presence of com-
pounds with structural modifications that lead to gradual changes 
in potency, whereas discontinuous SAR regions contain structural 
analogs with large (and essentially unpredictable) potency variations2.
Matrix distribution and ranking
Large compound data sets typically yield many SARMs of different 
size and composition, depending on their degree of structural 
homogeneity or heterogeneity. Two examples are given to illustrate 
this point. First, an in-house focused compound library with various 
substitutions of a small number of core structures comprising 6503 
compounds produced a total of 6738 (single-, double- and triple-cut) 
matrices containing a total of 135,619 VCs. Second, a structurally 
heterogeneous set of 509 purinergic receptor (P2Y12) ligands 
generated a total of 181 SARMs containing 17,445 VCs. Again, 
each SARM contains a unique A_MMS and individual compounds 
might belong to multiple A_MMS depending on the structural 
relationships they form. SARMs provide highly resolved views of all 
of these structural relationships. Depending on the number of 
compounds forming A_MMS, the size of SARMs can considerably 
vary. For example, in a survey of 32 different activity classes 
consisting of 398 to 2497 compounds, SARMs were found to 
contain between three and 555 compounds, with a median value of 
13. Furthermore, we also use a “matrix overlap” measure to account 
for the overlap between the corresponding substituents (columns) 
Figure 3. Matrix overlap distribution. Shown is a histogram with the matrix overlap distribution for SARMs from an in-house focused library.
in different A_MMS (rows), which typically varies in SARMs. 
Matrix overlap is determined as the average over all row overlap 
values. For individual columns in SARMs, row overlap (RO) is 
calculated as:
1
RO
# 1
n_col=
rows
−
−
where, n_col correspond to the number of data set compounds 
present in each column. RO yields a numerical score between 0 
(no overlap) and 1 (complete overlap). Figure 3 reports the matrix 
overlap distribution for SARMs from the focused library referred to 
above, which is a fairly representative distribution for structurally 
homogeneous data sets. Here 5% of the SARMs have an RO of 0 for 
each column; hence, the final matrix overlap score is 0 indicating 
the mutually exclusive nature of the substitution pattern among the 
A_MMS. By contrast, 30% of the SARMs have an RO of 1 for each 
column; hence, the final matrix overlap is 1 reflecting the presence 
of A_MMS with identical substitution patterns. As an alternative 
measure, “matrix coverage” (C), which accounts for the propor-
tion of cells in a SARM that are populated with real compounds 
n_matrix can be calculated as:
C
# *#
n_matrix=
rows columns
Regardless of the number of SARMs that are obtained from large 
data sets, there are too many for one-by-one inspection. Hence, 
ranking schemes should be applied to prioritize and pre-select 
those SARMs that are most informative for a given application. For 
instance, SARMs can be easily ranked on the basis of numerical 
functions that prioritize matrices containing preferred substituent 
combinations or core structures and SAR transfer events or matrices 
that capture high degrees of local SAR continuity or discontinuity. 
For example, Figure 4 shows two SARMs originating from a large 
data set that are highly ranked on the basis of SAR discontinuity 
Page 6 of 14
F1000Research 2014, 3:113 Last updated: 05 JAN 2015
Figure 4. Ranked SAR matrices. In (a) and (b), two SARMs are shown (resulting from single- and triple-cut fragmentation, respectively) for 
corticotropin-releasing factor receptor 1 ligands that were highly ranked on the basis of SAR discontinuity scoring.
(as indicated by the presence of multiple analogs with large potency 
differences). Depending on the applied selection criteria, most in-
formative SARMs can be readily inspected on the basis of a ranked 
list.
Compound design and activity prediction
VCs contained in SARMs provide immediate suggestions for com-
pound design. Because VCs represent unexplored key-value com-
binations derived from data set compounds, the union of VCs 
from all SARMs provides a “chemical space envelope” for a given 
compound set or library. VCs originating from SAR-informative 
matrices represent natural focal points for interactive compound 
design. Moreover, the potency of many virtual compounds can be 
predicted by applying a compound neighborhood (NBH) princi-
ple5, as illustrated in Figure 5. An NBH of a given VC is defined 
by three adjacent real compounds that contain the core of the VC 
(compound G in Figure 5), its substituent (compound E) and the 
core and substituent of G and E (compound D). The potency of the 
VC can then be predicted by applying the additivity assumption 
underlying Free-Wilson analysis9 using the simple equation shown 
in Figure 5. The putative potency value of the VC results from the 
sum of (logarithmic) potencies of the two real compounds shar-
ing the same core and substituent with the VC, respectively, minus 
the potency of the compound that contains the core structure and 
substituent of the two other real compounds. Thus, from NBHs, 
“mini-QSAR” models are derived for activity prediction. For each 
candidate VC, qualifying NBHs are collected across all SARMs, 
individual potency predictions are carried out, and their consist-
ency is evaluated, for example, by calculating standard deviations 
for predictions5. In benchmark calculations on six different sets of 
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Figure 5. Neighborhood-based potency prediction. An NBH of virtual compound X is marked in blue in a model SARM and displayed in 
detail. Compounds E and G share the same substituents and core with X, respectively, and the third neighbor D combines the core and 
substituent of E and G, respectively. At the bottom, the equation to predict the potency of X from the potency values of E, G, and D is shown.
G protein-coupled receptor ligands, potency values of subsets of 
test compounds falling into continuous local SAR regions were 
accurately predicted using the NBH-based approach, and prediction 
accuracy generally increased with the number of qualifying NBHs5. 
This is also relevant for practical applications. For potency predic-
tion, candidate VCs should be prioritized for which multiple NBHs 
are available. For example, for the set of 509 purinergic receptor 
ligands (vide supra), 5167 of 17,445 VCs were found to have at 
least three qualifying NBHs. Hence, in these cases, the consistency 
of potency predictions can be assessed. Such candidate VCs can be 
explored in a systematic manner. For libraries tested in individual 
assays, VCs predicted to be consistently active on the basis of mul-
tiple NBHs provide preferred candidates for target/assay-dependent 
library expansion and focusing.
Importantly, the NBH-based mini-QSAR approach is only applicable 
to candidate compounds falling into SARMs that represent continu-
ous SAR regions, as illustrated in Figure 6a. By contrast, compounds 
falling into discontinuous SAR regions, as shown in Figure 6b, 
fall outside the applicability of standard QSAR modeling. Nonethe-
less, VCs from SARMs representing discontinuous SAR regions 
are also attractive candidates for compound design. This especially 
applies to VCs falling into the vicinity of activity cliffs10 that are 
formed by pairs of structural analogs with large potency differ-
ences, as illustrated in Figure 6b. Activity cliffs represent the pin-
nacle of SAR discontinuity. VCs in the vicinity of activity cliff can 
often be expected to display large (positive or negative) potency 
fluctuations and are hence attractive candidates in the search for 
potent hits. Although a QSAR formalism cannot be applied to pre-
dict the potency of such compounds, they can be easily selected 
from SARMs containing activity cliffs on the basis of a “guilt-by-
association” principle, i.e., VCs are preferentially selected that are 
neighbors of potent activity cliff partners. For this purpose, SARMs 
capturing high degrees of local SAR discontinuity are selected on 
the basis of discontinuity ranking (vide supra).
Figure 6. Candidate compound selection and activity prediction. 
In (a), a SARM is shown that represents a highly continuous local 
SAR environment. In this case, the potency of a virtual compound 
can be predicted using the NBH-based approach. By contrast, (b) 
shows a SARM representing a discontinuous local SAR. Activity 
cliff-forming compound pairs are highlighted in blue. Such SAR 
environments fall outside the applicability domain of NBH-based 
potency predictions. However, marked VCs represent promising 
candidates for compound design based on their proximity to activity 
cliffs. Both SARMs originate from a set of cannabinoid CB1 receptor 
ligands (compound structures are omitted for clarity).
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Multi-target activity spaces
SARMs have also been adapted for the navigation of multi-target 
activity spaces, which are populated by promiscuous compounds. 
In this context, promiscuity is defined as the ability of a compound 
to specifically interact with multiple targets (as opposed to non-
specific binding effects)11. Here, the primary purpose of the matrix 
approach is not SAR analysis, but the systematic exploration of 
compound promiscuity patterns. Therefore, matrices capturing 
multi-target activities are generated. Such matrices have been des-
ignated as Compound Series Matrices (CSMs)6. CSMs are of interest 
for chemogenomics applications in which compound-target inter-
actions are systematically explored12. In Figure 7, two exemplary 
CSMs of different composition and target coverage are shown that 
reveal different compound promiscuity patterns. In CSMs, data set 
compounds are color-coded according to the number of targets they 
are active against (instead of potency-based coloring). In Figure 7a, 
Figure 7. Multi-target compound series matrices. (a) shows a CSM containing 15 inhibitors of 10 carbonic anhydrase (CAR) isoforms. 
Target coverage of analogs is reflected by increasingly dark blue shading of cells. Substructures distinguishing the core fragments are 
highlighted in red. The matrix composition is summarized (top left) and the target profile reported (top right). (b) shows a CSM with 44 analogs 
active against 10 targets (including the hERG anti-target) belonging to three different families. The maximum common core structure (MCS) 
of the analog series is displayed. For clarity, compound structures are omitted. Target abbreviations: 5-HT; serotonin receptor, ST; serotonin 
transporter, D; dopamine receptor, hERG; hERG ion channel.
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two structural analogs display very different degrees of promiscuity 
and in Figure 7b, a center of promiscuity is identified in a sparsely 
populated matrix. CSMs are designed to mine chemogenomics data 
sets and also offer immediate suggestions for the design of com-
pounds with different multi-target activities. In addition, it is also 
readily possible to deconvolute CSMs into individual single-target 
SARMs, as illustrated in Figure 8. This makes it possible to com-
pare SARMs across different targets and identify compounds that 
are attractive candidates for testing against additional targets.
Programs and compounds
Java programs were written, in part with the aid of the OpenEye 
chemistry tool kit13, to identify A_MMS and generate, rank, and 
display SARMs. Routines for potency predictions were also imple-
mented in Java. Statistical analyses were carried out using R14. All 
compounds shown herein were obtained from ChEMBL15.
Concluding remarks
Herein, we have reviewed the design of the SARM methodology 
and discussed recent extensions and selected applications. In-house 
implementations of the SARM approach have been continuously 
developed and further refined to increase the utility of the method-
ology for medicinal chemistry. Primary reasons for discussing the 
different aspects and applications of SARMs in context have been 
to expose this approach to a wider drug development audience and 
provide an example for the data- and application-driven evolution 
of a computational medicinal chemistry method. SARMs can essen-
tially be rationalized as local activity landscapes of data sets that 
are based upon a unique and comprehensive structural organization. 
SARMs primarily focus on activity information associated with 
series of closely related compounds but can also be applied to sys-
tematically study compound promiscuity patterns. In addition, they 
can also be easily adapted to explore other structure-property rela-
tionships relevant to drug discovery. A special feature of SARMs 
that sets them apart from many other activity landscape representa-
tions is that they closely link descriptive compound data analysis 
(a primary task of activity landscape modeling) and prospective 
compound design. Because SARMs are reminiscent of convention-
al R-group tables, they are readily intuitive to medicinal chemists, 
thus circumventing the communication barrier that often hinders 
the effective application of computational approaches in the prac-
tice of medicinal chemistry. Future research activities will focus on 
Figure 8. Matrix conversion. The deconvolution of a CSM with eight analogs active against the dopamine D2, D3, and D4 receptor isoforms 
into three single-target SARMs is illustrated. In all matrices, cells corresponding to VCs are not color-coded. In SARMs, cells of compounds 
with no available activity annotation for a given target are colored gray.
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This is a well written article with a sound description of the Structure-Activity Relationship (SAR) Matrix
(SARM) methodology. Only a few questions / suggestions are recommended.
In the Methods section, you describe the definition of a MMP. Specifically, you rely on the
algorithm by Hussain and Rea. Have you considered MMPs where the only change is in a ring (i.e.,
an aromatic versus partially saturated ring)?
 
Continuing onwards in the Methods section, you extend the MMP concept to include Matched
Molecular Series (MMS). While I believe you were the first to coin this description, there are now
others who are also using this formalism (e.g.  (Roger Sayle)) and some reference toNextMove
these additional methods is advised, particularly to avoid confusion since the names are similar. If
there are differences, perhaps you could expand on them.
 
In the Matrix distribution and ranking section, could you expand on the matrix overlap, row overlap
and matrix coverage with at least one specific example (ie show the math in the supplementary
material)? Additionally, I recommend using the same variables (i.e. are " " and " "n #real compounds
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material)? Additionally, I recommend using the same variables (i.e. are " " and " "n #real compounds
the same)? If so, then they should be consolidated to one variable.  Additionally, it's not obvious
how the numbers to the right (5%) and left (30%) of the two matrices are derived.
 
There appears to be some mis-counting of the number of targets in both Figure 7a & b. For Figure
7a, are there 10? And for Figure 7b, we count 10 targets and 4 families. Make sure to check the
Figure 7 caption. Consider referring to DOP-D2 as merely D2; likewise DOP-D3 should be merely
D3. Check the commas and semicolons as there are inconsistencies.
 
Can these multi-target compound series matrices be tied to Adverse Drug Reactions (ADR)?  That
seems as a possible extension of this current work. In Figure 7b you consider hERG and hence, it
seems as an opportunity to extend beyond merely the primary activity.
 
Consider changing the word " " in the concluding remarks to "intuitive" or "interpretable".accessible
We have read this submission. We believe that we have an appropriate level of expertise to
confirm that it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
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 Herman van Vlijmen
Janssen Infectious Diseases-Diagnostics BVBA, Beerse, Belgium
The manuscript on the SAR matrix method offers a useful approach to extract the relevant information
from large datasets with compound activity data, and to present this in an intuitive way to chemists and
computational chemists. It is therefore an attractive tool to use in analysis of HTS screens and to find
structure activity trends and discontinuities in large groups of structurally related molecules.
The title and abstract cover the content well. The chemogenomics application of the method is related to
the use of compound promiscuity instead of the more usual compound activity on a single target. The
methods are clearly described and can most likely be reproduced. The datasets used (even the dataset
from the public source CHEMBL) are not provided, so the results will be difficult to reproduce. There is no
mention in the manuscript on the availability of the tools that were developed. Methods like these could
get widespread usage if they would be available to a wider audience. It would also be good if at least the
public dataset would be made available so the results can be compared to other approaches.
One significant benefit of this approach is that a large dataset can automatically be processed by the
method to create multiple (often very many) SAR matrices. The authors point out that the idea is not that
all these (often hundreds or thousands) SAR matrices are inspected visually, but that interesting elements
in the matrices can be identified automatically, for instance "virtual compounds" (core-substituent
combinations not yet made) that are predicted to have interesting activity. The same virtual compound
can appear in different SAR matrices, and therefore multiple predictions can be made for the same
compound and the level of consistency could be a good indicator for deciding to make he actual
compound. The method also automatically identifies virtual compounds that are close to activity cliffs and
are therefore interesting to make and test.
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CHAPTER 3: SUMMARY
Summary
An overview of the SARM methodology and its extensions has been provided
primarily to increase awareness in the drug development audience. The evolu-
tion of this method is driven by the available data and its application. In this
Chapter, new data was analyzed using the SARMs and CSMs and made public.
My contribution to this work herein included the generation and the analysis
of SARMs and CSMs.
The detailed study of the SARM-based data mining method, which is used to
navigate high-dimensional activity spaces, will be further discussed in Chapter
4.
The predictive approach that helps to prioritize VCs systematically and
further enhances the utility of SARMs will be further discussed in Chapter 5.
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Chapter 4
Systematic Mining of Analog
Series with Related Core
Structures in Multi-Target
Activity Space
Introduction
Many bioactive compounds have multiple target annotations indicating that
compound promiscuity is a general phenomenon.4 The study of compound-
target interactions are crucial to identify the targets against which untested
compounds should be tested.
In this study, closely related analog series that are active against multi-
ple targets are identified. The SARM mining method is adapted to extract
such series from compound data sets. Here, the method is utilized to identify
compound promiscuity patterns among structurally related compounds.
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Abstract We have aimed to systematically extract analog
series with related core structures from multi-target activity
space to explore target promiscuity of closely related
analogous. Therefore, a previously introduced SAR matrix
structure was adapted and further extended for large-scale
data mining. These matrices organize analog series with
related yet distinct core structures in a consistent manner.
High-confidence compound activity data yielded more than
2,300 non-redundant matrices capturing 5,821 analog ser-
ies that included 4,288 series with multi-target and 735
series with multi-family activities. Many matrices captured
more than three analog series with activity against more
than five targets. The matrices revealed a variety of pro-
miscuity patterns. Compound series matrices also contain
virtual compounds, which provide suggestions for com-
pound design focusing on desired activity profiles.
Keywords Analog series  Core structures 
Structural relationships  Compound activity data 
Matched molecular pairs  Matching molecular series 
Compound series matrix  Biological targets
Introduction
In medicinal chemistry, analog series are usually organized
in tables that list R-groups at different sites of a molecu-
lar core shared by a given compound series and report
corresponding activity values [1]. These tables represent a
standard format for SAR analysis. Derivatives of SAR tables
have been introduced that organize compound series on the
basis of R-group decomposition and display activity data of
analogous in a heat map format [2] or in network represen-
tations [3]. In addition, approaches that utilize maximum
common substructures (MCSs) [4] or scaffold-based com-
pound organization schemes [5–7] are also widely used to
represent SAR data. Going beyond the traditional medicinal
chemistry focus on single series, methods for the extraction
of SAR information from large and heterogeneous com-
pound data sets have been developed in recent years [8]. In
this context, SAR matrices have been introduced [9], which
capture two or more compound series and display their
potency distribution in a colour-coded matrix format. SAR
matrices were originally designed to display potency pat-
terns in compound series active against a given target [9].
The SAR matrix data structure utilizes the matched molec-
ular pair formalism [10, 11] for the organization of analog
series with related core structures.
There is increasing evidence that many bioactive com-
pounds and drugs specifically interact with multiple targets
[12, 13], which extends the traditional single-target focus
of medicinal chemistry. Compound promiscuity is inten-
sely studied in pharmaceutical research [14] because it
provided the molecular basis of polypharmacology [15]. In
recent studies, many compounds with multi-target activi-
ties have been identified through data mining [14]. We
have been interested in extracting analog series with multi-
target activities from currently available active compounds
and capturing promiscuity patterns associated with closely
related analog series. For systematic mining of such series
and the graphical analysis of promiscuity patterns, the SAR
matrix data structure [9] has been adapted and further
extended.
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Materials and methods
Matched molecular pairs
Matched molecular pairs are defined as pairs of com-
pounds that are distinguished by the exchange of a single
fragment (substructure) at a specific site [10] referred to as
a chemical transformation [11]. Distinguishing fragments
include R-groups or ring systems and can vary in size.
MMPs were systematically calculated using an in-house
implementation of the algorithm by Hussain and Rea [11].
All molecules were initially subjected to fragmentation at
exocyclic single bonds, so-called single-cuts [11]. The
resulting two fragments were stored in an index table as
key-value pairs. The larger fragment constituted the key
and the corresponding smaller fragment constituted the
value. If the two fragments had the same size, each frag-
ment was stored once as a key and the corresponding
fragment as a value. If a newly generated key was already
contained in the index table, the corresponding value was
added to the existing key. For a small compound set shown
in Fig. 1a, the generation of the MMP index table is
illustrated in Fig. 1b.
Structurally analogous matching molecular series
Matching molecular series (MMS) have previously been
introduced as an extension of the MMP concept [16]. An
MMS comprises a series of compounds that share the same
core (key) and differ by defined chemical substitutions
(values). In addition, structurally analogous MMS are
defined here as two or more MMS whose core structures
(keys) differ at a single site [16]. For the systematic identi-
fication of such structurally related MMS, the keys in the
index table were subjected to a second round of fragmenta-
tion including all exocyclic single bonds and all combina-
tions of two and three single bonds (so-called dual- and
triple-cuts, respectively). Dual-cuts yield three and triple-
cuts four fragments. Four-fragment combinations were only
retained if they consisted of three fragments with single
attachment points and a fragment with three attachment
points. Figure 1c illustrates the generation of analogous
(b)(a)
(c)
(d)
Fig. 1 MMP and matrix generation. a A set of 12 test compounds is
shown. b MMP index table derived from these compounds form four
MMS (A, B, C and D). c Three of these MMS (A, B, and C) that are
structurally analogous are revealed by the index table. d CSM
representing the three structurally analogous MMS. Distinguishing
fragments in the structurally related cores are highlighted in red
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MMS from keys in the original index table (Fig. 1b) through
double-cut fragmentation.
Figure 2 shows three exemplary MMS that are further
transformed into Bemis–Murcko (BM) scaffolds [17] by
removing R-groups from compounds as well as cyclic skele-
tons (CSKs) [18] by setting all bond orders in BM scaffolds to
one and converting all heteroatoms to carbon. Structurally
analogous MMS are generally difficult to identify because
maximum common substructure methods are not feasible in
this case to capture related series. However, they can be sys-
tematically identified by applying the MMP-based double-
fragmentation procedure described above.
Compound series matrix
MMS that are structurally analogous are combined in a
matrix in which rows are formed by keys and columns by
corresponding values, as illustrated in Fig. 1d. Each com-
bination of a key and value fragment defines an individual
compound. Compounds present in the same row form an
individual MMS. The matrix format was adapted from SAR
matrices [9] that were designed to analyze SAR information
contained in analog series focusing on compound potency, as
illustrated in Fig. 3 (left). Here, the matrix structure was
utilized for data mining and used to systematically extract all
analog series with multi-target activities from currently
available active compounds. Accordingly, the matrix struc-
ture is termed compound series matrix (CSM). For matrix
annotation, all target annotations were collected for available
active compounds. Cells in a matrix were color-coded
according to the number of targets that compounds were
active against, as shown in Fig. 3 (right).
As a consequence of the systematic fragmentation pro-
cedure, it is possible that a compound is represented mul-
tiple times in matrices as distinct key-value combinations.
Therefore, compound redundancy in matrices is minimized
as follows:
1. If keys of key-value combinations representing the
same compound form substructure relationships, only
the larger key fragment is retained.
2. If two MMS sharing the same value fragments yield
identical compounds, one of these series is randomly
selected and removed.
3. If two different value fragments in an MMS yield the
same compounds, the value fragment associated with
the smaller number of compounds is removed.
Fig. 2 Structurally analogous
matching molecular series.
Shown are three exemplary
analog series (MMS) with
structurally related yet distinct
cores. Corresponding
substituents are highlighted in
blue and modifications that
distinguish related core
structures in red. The generation
of BM scaffolds and CSKs from
analogs is shown at the bottom
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Matrix coverage
Matrix coverage C defines the proportion of CSM cells that
are populated with known active (‘‘real’’) compounds.
C ¼ n= rows  columnsð Þ
Here, n gives the number of populated matrix cells and
rows and columns refer to the numbers of rows (keys) and
columns (values) forming the matrix. Coverage values
range from 0 to 1 and reflect matrix population density for
known compounds.
Importantly, by design CSMs consist of known active
compounds and virtual compounds that extend/complement
structurally related series but are not yet available. As further
discussed below, virtual compounds are highly relevant for
CSM analysis because they provide compound design sug-
gestions. Accordingly, the matrix coverage parameter pro-
vides a measure for virtual compound content of CSMs; the
larger C, the larger the population density for real com-
pounds in a given matrix; the smaller C, the sparser the
matrix and the larger the population of virtual compounds.
Thus, CSMs can be ranked on the basis of matrix coverage.
For example, CSMs with larger coverage are prioritized if
one searches for extensively explored core structures and/or
chemical substitutions. Alternatively, CSMs with smaller
coverage are preferred if one searches for opportunities to
design new analogs of active compounds or series of interest.
Matrix generation
Keys from original set of MMS comprising of at least three
compounds were subjected to a second round of frag-
mentation to generate CSMs formed by structurally anal-
ogous MMS. A CSM was required to contain a minimum
of two MMS with at least three compounds each. CSMs
comprising compounds that were subsets of other larger
matrices were discarded to minimize matrix redundancy. If
CSMs consisted of the same set of compounds, the matrix
with larger coverage and larger average key size was
retained to prioritize analogs with smaller substituent
exchanges.
Implementation
Routines required to build the index tables, identify anal-
ogous MMS, generate CSMs, and visualize matrices were
implemented in Java using OpenEye tool kits [19, 20].
Fig. 3 Matrices of different
design concept. A schematic
comparison of the SAR matrix
method and its CSM extension
for mining of multi-target
activity space is shown
668 J Comput Aided Mol Des (2013) 27:665–674
123
Author's personal copy
Data sets
Compounds containing rings and a maximum of 45 acyclic
single bonds with activity against human targets were
extracted from ChEMBL (release 15) [21]. Compounds
with direct target interactions, available Ki values, and a
potency of at least 10 lM were selected and their Ki
measurement-based target annotations were compiled.
Results and discussion
Study concept
This matrix format was originally introduced as the so-
called SAR matrix [9] to monitor potency distributions of
analogs active against a given target in series using
potency-based color-coding of matrix cells, as illustrated
on the left in Fig. 3. SAR matrices were prioritized if they
contained many highly potent compounds or displayed
SAR discontinuity [9]. Here, we do not utilize the matrix
format for SAR analysis but rather adapt the data structure
for systematic mining of related compound series in high-
dimensional target space, as illustrated on the right in
Fig. 3. Transitioning from SAR analysis of single-target
compound sets to systematic mining of compound activity
data in multi-target space required methodological exten-
sions. In CSMs, an alternative color code was introduced
focusing on multi-target activities and efficient compound
and matrix redundancy tests were implemented. CSMs
were primarily designed to map structurally related analog
series in target space, capture multi-target activities asso-
ciated with closely related compounds, and reveal (visu-
alize) promiscuity patterns. Furthermore, we emphasize
another previously unconsidered aspect of matrix mining.
Analysis of CSMs makes it possible to bridge between data
mining and compound design by focusing on virtual
compounds contained in matrices that complement existing
series. Depending on their matrix environment and multi-
target activity patterns of neighboring compounds, virtual
CSM compounds can be prioritized that are likely to dis-
play desired activity against selected targets, as further
discussed below.
Analog series with related core structures
In Fig. 2, exemplary MMS are shown that are by definition
characterized by the presence of closely related yet distinct
core structures and corresponding substituents. In this
study, we have aimed to systematically identify and char-
acterize such series, which are of particular interest for a
comparative SAR analysis and practical medicinal chem-
istry applications, yet difficult to extract from databases. To
these ends, we have adapted an MMP-based dual-frag-
mentation approach to identify structurally related MMS
and organize them in CSMs, as detailed in Methods
section.
Mining compound series matrices
On the basis of our selection criteria, 37,850 unique com-
pounds were obtained having a total of 62,784 target
annotations. The number of target annotations per com-
pound ranged from one to 35 and the compounds were
active against a total of 342 targets.
From the pool of 37,850 compounds, CSMs were sys-
tematically generated and a total of 2,337 non-redundant
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Fig. 4 Compound series matrix content. a The number of CSMs
containing increasing numbers of MMS (rows) is reported in a
histogram. b The distribution of BM scaffolds (gray) and CSKs (red)
over CSMs is reported. c For all CSMs, matrix coverage is reported
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matrices were obtained. The structurally related compound
series forming each of these matrices are made freely
available via the following URL: http://www.lifescience
informatics.uni-bonn.de.
Matrix composition
Figure 4a reports the distribution of MMS (rows) over
CSMs. The majority of CSMs, i.e., more than 1,300, con-
tained two MMS. In addition, more than 600 and 200
CSMs consisted of three to four and five to six MMS,
respectively. Matrices with seven to 14 MMS were also
frequently obtained and individual CSMs with more than
20 series were identified. In total, the CSMs represented
5,821 unique MMS. Among these MMS, there were 4,288
series with multi-target activities, 735 of which were active
against targets from different families.
Figure 4b reports the distribution of BM scaffolds and
CSKs for all CSMs. Among 2,337 CSMs, a total of 180 and
260 CSMs contained compounds that were represented by
the same BM scaffolds and CSKs, respectively. The
remaining *89–92 % of CSMs contained multiple core
structures yielding different scaffolds and CSKs. More-
over, 689 and 369 CSMs were found to represent more than
nine BM scaffolds and CSKs, respectively. On average,
CSMs contained compounds with nine scaffolds and six
CSKs, respectively.
Figure 4c reports the coverage of CSMs. The distribu-
tion displays a peak at a coverage value of 0.5. Hence, in
these matrices, 50 % of all theoretically possible analogs
were present, providing opportunities for the exploration of
additional analogs. CSMs with higher coverage were also
frequently observed. Figure 5 shows two model CSMs that
yielded MCSs of comparable size and contained the same
number of MMS and value fragments. However, these
CSMs were distinguished by different degrees of coverage,
i.e., 0.86 versus 0.53. White cells represent virtual com-
pounds combining key and value fragments that occurred
in other compounds. Virtual compounds that are adjacent
(a) (b)Fig. 5 Compound series
matrices with different
coverage. Two model CSMs are
shown containing the same
number of series and
substituents but having different
matrix coverage. For both
CSMs, the maximum common
substructure (MCS) is given.
Cells are shown in gray if they
represent data set compounds
and white if they represent
virtual compounds. Cells
yielding promising compound
design suggestions are
highlighted in red
Fig. 6 Mining multi-target activity space. At the top, all generated
CSMs are classified according to single- and multi-target activities. At
the bottom, the distribution of CSMs annotated with increasing
numbers of targets is reported distinguishing between single- (gray)
and multi-family (red) activity
670 J Comput Aided Mol Des (2013) 27:665–674
123
Author's personal copy
in the matrix to data set compounds with desired (multi-
target) activity (highlighted in Fig. 5) provide promising
compound design suggestions.
Target distribution
Major goals of this study have been to mine multi-target
activity space using CSMs and identify structurally related
analog series with activity against increasing numbers of
targets. As reported in Fig. 6, *29 % of CSMs (682) were
composed of compounds with single-target activity. By
contrast, a total of 1,064 CSMs identified compounds with
activity against multiple targets from the same family.
Unexpectedly, 591 CSMs were also found to contain com-
pounds active against targets from two to 11 different fami-
lies. The target distribution is reported at the bottom of Fig. 6.
CSMs containing compounds with reported activity against
two to five targets were frequently observed and smaller
(a)
(b)
Fig. 7 Single- and multi-target compound series matrices. a Single-
target CSM with analogs active against anandamide amidohydrolase.
The MCS of all series is shown. The CSM label (top left) reports the
number of MMS, targets the matrix compounds are active against,
families these targets belong to, and the total number of analogs.
b Multi-target CSM with analogs active against 20 targets belonging
to four families. Target coverage of analogs is reflected by
increasingly dark blue shading of cells. The histogram at the bottom
reports the number of matrix compounds with activity against
increasing numbers of targets
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numbers of CSMs covered a wide range of up to more than 20
targets. On average, CSMs displayed activity against four
targets. In general, the proportion of multi-family CSMs
increased with the increasing numbers of targets.
Thus, a large number of multi-target CSMs was identi-
fied that captured activity of closely related analog series
against targets from different families. The CSM-based
identification and structural organization of these series
(a)
(b)
Fig. 8 Compound series matrices representing the same target
profile. In a and b, two exemplary CSMs cover structurally distinct
series with activity against the same targets. a CSM containing two
MMS with eight compounds. b CSM containing seven MMS with 36
compounds with activities against 2–5 targets. The representation is
according to Fig. 7. Substructures distinguishing the core fragments
are highlighted in red. The series in these two matrices display
different promiscuity patterns. Target abbreviations: ST serotonin
transporter, NT norepinephrine transporter, DT dopamine transporter,
MAR-M4 muscarinic acetylcholine receptor M4, MAR-M5 muscarinic
acetylcholine receptor M5, HERG HERG ion channel. Cells in the
two matrices with reported activity against the HERG anti-target are
highlighted in red
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made it possible to study compound promiscuity patterns in
detail.
Promiscuity patterns
In Fig. 7, two exemplary CSMs capturing analog series
with single-target activity or target promiscuity are shown.
In Fig. 7a, the single-target CSM contained 10 MMS and
50 compounds that were active against anandamide ami-
dohydrolase. By contrast, the larger CSM in Fig. 7b con-
tained 12 series with 123 analogs active against one to 12
targets. The histogram at the bottom of Fig. 7b reports the
distribution of target annotations for all analogs, revealing
a subset of 51 promiscuous compounds with activity
against increasing numbers of targets. In total, the com-
pounds were active against 20 unique targets belonging to
four different families. Hence, this example illustrates that
CSMs enable the detection of progressive target promis-
cuity patterns among analogs belonging to closely related
series.
Matrices representing the same target profile
As described above, multi-target CSMs were frequently
identified. In Fig. 8, two exemplary CSMs with different
core structures are shown that contain two and seven MMS,
respectively. These series consisted of different numbers of
analogs with activity against varying numbers of six targets
from three different families. For the majority of these
series, closely related analogs were found to be active
against overlapping yet distinct targets. These CSMs had
very different matrix coverage, i.e., 0.57 (Fig. 8a) versus
0.29 (Fig. 8b). Thus, the CSM in Fig. 8b provided more
opportunities to design analogs and ‘‘fill’’ the matrix.
However, compounds with HERG anti-target activity were
also found in these CSMs (highlighted in Fig. 8). Hence,
these compounds point at likely liabilities associated with
individual series, which would suggest to carefully inves-
tigate potential anti-target activities of closely related
analogs captured in these matrices.
Mapping of virtual matrix compounds to drugs
From the 2,337 CSMs reported herein, all virtual com-
pounds were extracted and mapped to 6,081 approved and
experimental drugs assembled from DrugBank [22]. A total
of 48 drugs were found to match virtual compounds
derived from 25 different matrices. Most of these drugs
were annotated with targets that overlapped with the target
profiles of the corresponding matrices. Hence, virtual
matrix compounds are a potential source of interesting drug
(-like) molecules.
Conclusions
In this study, we have searched for closely related analog
series with multi-target activities by applying the CSM
concept and described promiscuity patterns emerging from
these series. CSMs represent multiple structurally analo-
gous series and closely related virtual compounds in a well-
defined manner. Moreover, the matrix data structure was
used here for systematic compound data mining and the
exploration of multi-target activity space on the basis of
currently available bioactivity data. Virtual analogs adja-
cent to compounds with desired activities yield design
suggestions. We have identified 4,288 series with diverse
multi-target and 735 series with multi-family activities.
The identification of these series in CSMs and their
structural organization makes it possible to analyze pro-
miscuity patterns at the level of structurally related ana-
logs. All CSMs are made freely available to provide a basis
for further analysis of analog series with multi-target
activities.
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CHAPTER 4: SUMMARY
Summary
In this study, the SARM mining method was used to identify structurally re-
lated compound series active across multiple targets and to analyze promiscuity
patterns among them. 2,337 compound series matrices of varying structural
and activity composition were identified from high-confidence compound activ-
ity data. These compound series matrices identified 4,288 series representing
multi-target and 735 series representing multi-family activities. Furthermore,
the compound series matrices can also be used to create virtual compounds
that provide opportunities to guide the design of novel compounds with desired
multi-target activities. My contribution to this study has been the design and
the analysis of the compound series matrices.
The following study in Chapter 5 describes a novel method for systematically
predicting the activity of virtual compounds from SARMs.
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Chapter 5
Neighborhood-Based Prediction
of Novel Active Compounds
from SAR Matrices
Introduction
Virtual compounds resulting from SARMs are difficult to prioritize based on
just visual inspection of the matrices. Here, we introduce a methodology to
predict and prioritize virtual compounds by systematically utilizing the activity
information from their neighborhoods in SARMs. This is done by considering
individual contributions of cores and substituents of compounds in qualifying
neighborhoods. This approach is well suited for potency prediction during
compound optimization considering multiple analog series. Benchmark studies
for method evaluation are carried out on six large data sets of G protein coupled
receptor antagonists.
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ABSTRACT: The SAR matrix data structure organizes compound data sets according
to structurally analogous matching molecular series in a format reminiscent of
conventional R-group tables. An intrinsic feature of SAR matrices is that they contain
many virtual compounds that represent unexplored combinations of core structures
and substituents extracted from compound data sets on the basis of the matched
molecular pair formalism. These virtual compounds are candidates for further
exploration but are difficult, if not impossible to prioritize on the basis of visual
inspection of multiple SAR matrices. Therefore, we introduce herein a compound
neighborhood concept as an extension of the SAR matrix data structure that makes it
possible to identify preferred virtual compounds for further analysis. On the basis of
well-defined compound neighborhoods, the potency of virtual compounds can be
predicted by considering individual contributions of core structures and substituents
from neighbors. In extensive benchmark studies, virtual compounds have been
prioritized in different data sets on the basis of multiple neighborhoods yielding
accurate potency predictions.
■ INTRODUCTION
The conventional approach to the exploration of structure−
activity relationships (SARs) in medicinal chemistry is the
organization of compound series in R-group tables.1 Such tables
record R-groups at different substitution sites of a core
structure common to a compound series and report activity
values of analogs. With the aid of R-group tables, new
compounds are designed on the basis of medicinal chemistry
experience and intuition. Simple comparisons of molecular
graphs typically provide a basis for studying similarities and
differences between active compounds and for identifying key
structural features that correlate with activity.1,2 In addition to
standard R-group tables, other hierarchical structural organ-
ization schemes have also been introduced for SAR exploration
that are based upon maximum common core structures3 or
molecular scaffolds.4,5
Computationally, the design of new compounds on the basis
of series information has traditionally been supported by
Quantitative SAR (QSAR) analysis methods.6,7 Following
established QSAR principles, mathematical models are derived
using descriptors of chemical structure and properties to
predict the effects of chemical substitutions on compound
potency. In addition, in recent years, graphical methods have
been increasingly employed to visually analyze SARs, often
going beyond individual compound series.8,9 However, SAR
visualization methods are generally descriptive in nature and do
not directly lead to compound predictions.
In addition to scaffold-based approaches and graphical
methods, the matched molecular pair (MMP) represents
another emerging concept in medicinal chemistry10,11 that is
highly relevant for SAR analysis. An MMP is generally defined
as a pair of compounds that differ only by a structural change at
a single site, i.e., the exchange of a pair of substructures.10
Applying the MMP formalism, a chemical change relating two
compounds to each other can be directly associated with
changes in different types of molecular properties including
biological activity.11,12 Even for large compound data sets,
MMPs can be efficiently generated algorithmically,13 hence
providing a comprehensive pairwise substructure-based organ-
ization scheme. For SAR analysis, the MMP concept has been
further extended by introducing matching molecular series
(MMS),14 which are defined as a series of compounds that only
differ by chemical changes at a single site. MMS can be utilized
to construct SAR networks and follow substructure changes
within and across compound series that lead to SAR
progression.14
As a data structure that combines intuitive SAR visualization
with the MMS concept and further extends this concept, the
SAR Matrix (SARM) has been recently introduced.15 SARM
provides an R-group table-like high-resolution view of
compound data sets that are automatically organized into
structurally related series, as illustrated in Figure 1. It consists of
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“real” data set and structurally analogous virtual compounds.
Herein, we introduce an approach to predict virtual compounds
and their actual potency values from SARMs on the basis of
compound neighborhood information.
In the following sections, we describe the SARM data
structure, introduce the prediction methodology, and report the
results of systematic potency predictions of virtual compounds
from SARMs of different data sets.
■ SAR MATRIX DESIGN PRINCIPLES
SARM generation involves a dual compound fragmentation
scheme resulting in two-level MMP generation.15 In the first
step, compounds are subjected to MMP fragmentation applying
the algorithm by Hussain and Rea,13 leading to the generation
of an index table with large key fragments (core structures) and
smaller value fragments (substituents). In the second step, the
cores in the index table are subjected to an additional round of
fragmentation. The resulting fragments are stored in a new
index table with the larger fragment as the key, analogously to
the first step. Hence, this dual fragmentation scheme identifies
compound series having structurally related cores termed
“structurally analogous MMS” (A_MMS),15 which further
extends the MMS concept. In Figure 1, three series A, B, and C
are shown, each of which contains a common core structure
and differs at a single site (highlighted in blue). The second
fragmentation step reveals that the core structures of these
three series are related and also only differ at a single site (red
substructures at the bottom). Hence, series A, B, and C form an
A_MMS, which is represented in a unique SARM. As illustrated
in Figure 1, the SARM is filled with structurally related cores
resulting from the second MMP generation step and
corresponding substituents resulting from the first step. Each
row in the matrix contains an individual compound series, and
each cell represents an individual compound (a unique
combination of a key and value fragment). Hence, by design,
SARMs are 2D matrices. The series comprising a SARM
typically have overlapping yet distinct sets of substituents,
giving rise to combinations of real (filled cells) and virtual
compounds (empty cells). As shown in Figure 1, a continuous
color spectrum is applied to capture the potency information of
real compounds. Alternatively, ligand efficiency values can also
be used.
Typically, a large compound data set yields multiple or many
SARMs. Depending on the algorithmic fragmentation
scheme,13 single-cut matrices (i.e., one exocyclic bond in a
compound is systematically deleted to yield key and value
fragments), dual-cut (two exocyclic bonds are simultaneously
deleted), and triple-cut matrices (three exocyclic bonds are
deleted) are separately generated.15 The resulting SARMs
provide a high-resolution organization of a compound data set
that accounts for all possible structural relationships between
compound series. In addition, virtual compounds contained in a
SARM represent as of yet unexplored key-value combinations
and hence provide immediate suggestions for new analogs. As
such, virtual compounds systematically captured by SARMs can
be rationalized as a “chemical space envelope” that delineates
regions surrounding a given data set in chemical space. The
appearance of SARMs is akin to R-group tables, which makes
them easily accessible to medicinal chemists and permits
simultaneous exploration of structurally related compound
series. In addition to SAR analysis, the SARM data structure has
Figure 1. SAR matrix. Three model compound series (A, B, and C) containing three compounds each are shown with their respective pKi values
(red). Compounds in a series share a common core structure and differ by substitutions at a single site (highlighted in blue). The three series contain
structurally related cores (bottom left; substructure differences between cores are highlighted in red). The SAR matrix is generated by combining
structurally related analog series. Rows and columns represent compounds that share the same core and substituent, respectively. In each cell, the
combination of a core and a substituent defines a unique compound. Compounds present in the data set are indicated by filled cells that are color-
coded according to potency using a continuous spectrum from red (low potency) over yellow (intermediate) to green (high). In addition, empty
cells indicate virtual compounds.
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also been adapted to navigate multitarget activity space and
study promiscuous compounds.16
The set of SARMs representing a larger data set typically
contains many virtual compounds (as further detailed below).
This raises the question which of these virtual compounds
might be prioritized as design suggestions? SARM in its original
conceptualization did not provide selection schemes for virtual
compounds. Therefore, we introduce a compound and potency
prediction approach to further improve the utility of SARMs for
compound prioritization and design, as described in the
following.
■ COMPOUND PREDICTION METHOD
A possible criterion for the selection of virtual compounds from
SARMs is their proximity to real data set compounds for which
target-specific activity information is available. The underlying
idea is that close proximity of a virtual compound to multiple
active compounds (i.e., the presence of close structural
relationships) increases the probability that this virtual
compound might also be active relative to other virtual
compounds for which no active neighbors are available. This
leads to the notion and assessment of defined compound
neighborhoods (NBHs).
Neighborhood Definition. A preferred NBH of a virtual
compound is defined as one that consists of three adjacent real
compounds, as illustrated in Figure 2a. Because all real
compound entries in a given column or row containing a
virtual compound are equivalent as potential neighbors, many
different three-compound NBHs might exist for a given virtual
compound. In general, an NBH of a virtual compound is
formed by any combination of three compounds present in the
data set of which one shares the core of the virtual compound,
the second its substituent, and the third the different core and
substituent of these two neighbors. An NBH of this
composition is depicted in Figure 2a. If one of these three
neighboring compounds is missing, the NBH is incomplete and
does not qualify for further analysis. NBHs within the same
SARM consist of structurally closely related data set
compounds, whereas NBHs from different SARMs might
consist of structurally dissimilar compounds.
A virtual compound might already be prioritized based on
the number of qualifying NBHs, which establish close structural
relationships to known active compounds. However, given the
composition of so-defined NBHs, one can go a step further and
attempt to predict the potency of a given virtual compound on
the basis of potency information of its neighbors.
Neighborhood-Based Potency Prediction. The pres-
ence of a three-compound NBH of a virtual compound makes
it possible to predict its potency based on a local model
utilizing the additivity assumption underlying Free-Wilson
analysis,17,18 as illustrated in Figure 2b. Following this
approach, the potency of virtual compound X can be predicted
from the sum of logarithmic potencies of compounds A and C,
which share the same substituent and core with compound X,
respectively, minus the logarithmic potency of compound B,
which represents the combination of the core structure and
substituent of compounds A and C, respectively:
= + −K K K Kp (X) p (A) p (C) p (B)i i i i
Hence, subtracting the potency of B from the sum of
potencies of A and B corrects for the contributions of the
structural fragments of A and C that are not contained in X.
Hence, in essence, the local models represent “mini-QSAR”
models. These Free-Wilson-type predictions are applicable to
any qualifying compound NBH. A virtual compound often (but
not always) occurs in multiple SARMs obtained for a given data
set. Therefore, all qualifying unique NBHs of each virtual
compound are systematically identified and subjected to
potency predictions, as illustrated in Figure 3. The number of
qualifying NBHs might be increased in subsequent iterations by
considering compounds with predicted potency for NBH
definition (e.g., by generating NBHs consisting of data set and
previously predicted compounds). However, prediction accu-
racy would likely be reduced in such cases.
Comparison with QSAR. The NBH-based prediction
concept introduced herein represents a local prediction
approach. Local Free-Wilson-type predictions are carried out
for all matrices with qualifying NBHs for given virtual
compounds. The method does not utilize chemical descriptors
such as Fujita-Hansch QSAR or models based on training sets
such as Fujita-Hansch and Free-Wilson QSAR. The NBH-
based prediction scheme exploits characteristic features of
SARMs. By design, all compounds contained in an individual
SARM are structurally closely related and hence qualify for
QSAR-like predictions of virtual compounds within the same
Figure 2. Compound neighborhood and potency prediction. (a) The
NBH of virtual compound X is marked in blue in the given matrix and
shown in more detail at the bottom. Cores and substituents
comprising the three compounds forming the NBH are depicted.
Compounds A and C share the same substituent and core with X,
respectively, and the third neighbor B combines the core and R-group
of neighboring compounds A and C, respectively. (b) Compound
structures and pKi values (red) of “real” neighbors are given, and
calculations are reported to predict the potency of virtual compound
X.
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matrix. In addition, NBH-based predictions do not depend on
the population density of data set compounds in a given SARM,
only on the presence of local NBHs. This represents an
important difference compared to standard QSAR modeling.
To predict virtual matrix compounds, QSAR models would
need to be built for individual SARMs and would require the
presence of sufficient numbers of data set compounds to
assemble meaningful training sets.
Applicability Domain. The prediction methodology
generally aims to prioritize virtual compounds as candidates
for synthesis. In the context of our analysis, preferred virtual
compounds would in principle be characterized by the presence
of many different NBHs that yield consistent potency
predictions. Most interesting would be compounds with
consistently predicted high potency. The consistency of
potency predictions can be assessed by calculating the standard
deviation (SD) of multiple independent predictions; low SD
values indicate consistent predictions. It should be noted that
low SDs do not necessarily correlate with high prediction
accuracy (i.e., predictions can be consistently incorrect). By
contrast, high SDs are indicative of inconsistent predictions.
Such predictions are likely to occur if virtual compounds have
many structurally analogous neighbors with large differences in
potency. In this case, virtual compounds map to regions of SAR
discontinuity8 including activity cliffs,8,19 and local QSAR-type
predictions are no longer applicable in a meaningful way.19,20
Discontinuous compound NBHs yielding predictions with high
SDs might still be attractive for the analysis of specific
compound environments in SARMs, as further discussed below.
However, they fall outside the applicability domain of QSAR
modeling and are hence deprioritized in our systematic potency
predictions (even if predictions from individual discontinuous
NBHs would indicate high compound potency).
■ IMPLEMENTATION, DATA SETS, AND
CALCULATION SETUP
Routines to generate SARMs were implemented with the aid of
the OpenEye chemistry toolkit,21 and potency prediction
routines were implemented in Java. Statistical analyses were
carried out with R.22
For benchmark calculations, six large sets of different G
protein coupled receptor antagonists were extracted from
ChEMBL (release 15)23 for which Ki values were available as
potency measurements. The targets, sizes, and potency ranges
of these data sets are reported in Table 1. These data sets
consisted of 1103−1850 compounds that formed SARMs. For
all data sets, all possible SARMs were calculated, producing
between 655 and 1109 matrices per set, as also reported in
Table 1.
Following SARM generation, the following prediction
protocol was established:
(i) One third of the compounds were randomly removed
from each data set, and all corresponding matrix positions were
converted into virtual cells.
(ii) All removed (“pseudovirtual”) compounds were
recorded as potential targets for predictions (original virtual
compounds contained in unmodified SARMs could not be
predicted in benchmarking).
(iii) For all “virtualized” cells from potential prediction
targets, qualifying compound NBHs were systematically
determined.
(iv) Compounds having at least three unique NBHs across
SARMs were selected, and potency predictions were carried out
on the basis of each NBH. Then, the consistency of predictions
was assessed.
■ RESULTS OF SYSTEMATIC PREDICTIONS
Following the protocol reported above, pseudovirtual com-
pounds having qualifying NBHs were identified across SARMs
generated for different data sets and systematic potency
predictions were carried out.
Prioritization of Pseudovirtual Compounds. Between
76 and 179 pseudovirtual compounds with at least three
qualifying NBHs were identified in SARMs obtained for the
different data sets, as reported in Table 2. For all of these
compounds, potency predictions were carried out for individual
NBHs, and SDs of the predictions were calculated. SD values
falling into the first quartile of the distributions of all SDs
within a data set were classified as low SDs, and the
corresponding pseudovirtual compounds were designated low
SD (L_SD) compounds. Figure 4 reports the distributions of
SDs of predictions for all L_SD compounds. Median SD values
were close to 0.5 pKi units for all data sets. Hence, alternative
Figure 3. Neighborhood mining. For virtual compound X, the set of
all NBHs (outlined in blue) in an SAR matrix is identified and
neighborhoods qualifying for potency predictions are determined. In
this example, four qualifying NBHs (1 to 4) are identified, and
predicted activities are indicated by squares color-coded according to
the spectrum in Figure 1.
Table 1. Data Set Statisticsa
target name TID # SAR matrix # cpds pKi range
dopamine D2 receptor 217 700 1419 3.0 to 10.2
adenosine A1 receptor 226 1104 1825 4.2 to 10.5
adenosine A2a receptor 251 957 1850 4.0 to 11.0
adenosine A3 receptor 256 1109 1547 4.1 to 11.0
melanocortin receptor 4 259 669 1103 3.9 to 9.4
histamine H3 receptor 264 655 1718 4.4 to 10.5
aFor each compound data set, the ChEMBL target ID (TID), the
number (#) of SAR matrices and compounds, and their pKi range are
reported.
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potency predictions for these compounds generally fell well
within 1 order of magnitude. Between 19 and 45 L_SD
compounds were obtained from ∼400 to ∼600 potential
candidates for the different data sets, as also reported in Table
2. By increasing the SD threshold beyond the first quartile of
the global distribution, additional compounds can be obtained.
However, for our proof-of-principle investigation, the number
of L_SD compounds in Table 2 was readily sufficient. On the
basis of our above considerations, L_SD compounds fell within
the applicability domain of local prediction models, and their
potency predictions were further analyzed.
Prediction Performance. In Figure 5, distributions of
prediction errors are reported for L_SD compounds from all
data sets. With very few exceptions, prediction errors associated
with potencies averaged over NBHs were well within 1 order of
magnitude with a median of only ∼0.25 order of magnitude.
This is further illustrated in Figure 6 by a comparison of
observed vs predicted potency values across the different
potency ranges captured by the data sets. Regardless of the
potency ranges, observed and predicted potency values were
consistently very similar. Hence, for prioritized compounds,
accurate potency predictions were obtained.
As control calculations, we also generated Free-Wilson
QSAR models using R22 for individual SARMs to predict
L_SD compounds they contained (as discussed above). In
these cases, data set compounds contained in a SARM were
used as a training set for deriving a matrix-based Free-Wilson
model. We then compared prediction errors of these Free-
Wilson models for L_SD compounds with NBH-based
predictions originating from the same SARM. In test
calculations on individual SARMs, we observed very similar
(low) prediction errors for matrix-based Free-Wilson and
NBH-based predictions, indicating that NBH information was
sufficient to achieve accurate predictions for L_SD compounds.
Neighborhood Frequency. L_SD compounds can also be
ranked according to the number of NBHs qualifying for
prediction. Compounds frequently predicted to have high
activity are generally the most interesting candidates for further
exploration. In Figure 7, potency predictions and the frequency
of NBHs are compared for individual L_SD compounds.
Compound data points are scaled in size according to
prediction errors. Depending on the data sets, individual
compounds were found to have a maximum of ∼10 to ∼30
NBHs across SARMs. If prediction errors exceeding 1 order of
magnitude were detected, they were exclusively observed for
virtual compounds having only three or four NBHs. With
further increasing numbers of NBHs, predictions became
increasingly accurate (and prediction errors typically very
small). These findings reflect a general relationship between
Table 2. Pseudovirtual Compounds and Potency
Predictionsa
TID # pseudovirtual cpds # prioritized cpds # L Sd cpds
217 473 91 23
226 608 179 45
251 616 126 32
256 515 146 37
259 367 76 19
264 572 134 34
aFor each data set (indicated by TID according to Table 1), the total
number (#) of pseudovirtual compounds (i.e., data set compounds
removed from matrices), number of prioritized virtual compounds
with at least three qualifying compound neighborhoods, and number
of prioritized virtual compounds yielding potency predictions with low
standard deviations (L_SD) are reported.
Figure 4. Standard deviations of predictions. Box plots report the
distributions of standard deviations (y-axis) of potency predictions for
single pseudovirtual compounds having at least three qualifying NBHs.
Data sets are indicated by TIDs according to Table 1 (x-axis).
Figure 5. Prediction errors. Box plots report the distributions of
prediction errors for individual pseudovirtual compounds yielding
potency predictions with low standard deviations (L_SD compounds).
Prediction errors were calculated on the basis of averaged predicted
pKi values and are reported on the y-axis as Δ pKi units relative to
observed compound potencies. On the x-axis, data sets are given.
Figure 6. Observed vs predicted potency values. Box plots report the
distribution of observed (blue) and mean predicted pKi values (pink)
for L_SD compounds for each data set.
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increasing numbers of qualifying NBHs and prediction
accuracy.
Exemplary Compounds and Predictions. In Figure 8,
potency predictions are reported for exemplary L_SD
compounds together with their NBH information. In Figure
8a, predictions are reported for a histamine receptor antagonist
for which 10 different NBHs were available. Despite different
potency distributions of data set compounds across the NBHs,
the nanomolar potency (pKi 9.0) of this pseudovirtual
compound was accurately predicted. Similarly, in Figure 8b,
an adenosine A3 receptor antagonist for which six qualifying
NBHs were available yielded an accurate potency prediction. By
contrast, in Figure 8c, another adenosine A3 receptor
antagonist is shown with only four available NBHs. Although
a very low SD value (0.15 pKi units) was also observed for
individual predictions in this case, the potency of the
Figure 7. Neighborhood counts vs potency predictions. For L_SD compounds from each data set (TID at the top), the number of NBHs qualifying
for predictions and the averaged predicted pKi value is reported. Compounds are represented as dots that are scaled in size according to prediction
errors (Δ pKi units), as indicated at the bottom.
Journal of Chemical Information and Modeling Article
dx.doi.org/10.1021/ci5000483 | J. Chem. Inf. Model. 2014, 54, 801−809806
compound was underpredicted in all four NBHs, yielding a final
prediction error of 1.2 orders of magnitude, one of the largest
errors observed; a rare case in our predictions of prioritized
compounds. For increasing numbers of NBHs qualifying for
prediction, only small errors were observed, as reported above.
For comparison, Figure 9 shows a compound yielding high
SD values over multiple predictions (hence falling outside the
Figure 8. Exemplary predictions. In (a) and (b), the structures and NBHs of a histamine and adenosine A3 antagonist are shown, respectively, for
which accurate potency prediction were obtained. In (c), adenosine A2 antagonist is shown for which a prediction error of more than 1 order of
magnitude was observed. All three examples are L_SD compounds. Cells in NBHs are annotated with pKi values of corresponding compounds. Cells
framed in blue represent pseudovirtual compounds with predicted potency values.
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applicability domain of our approach). These predictions are
characterized by the presence of NBHs falling into
discontinuous local SAR regions. Although potency values
cannot be accurately predicted for such NBHs, virtual
compounds mapping to such regions might still be attractive
prediction targets because large potency fluctuations are
expected for such compounds (and one might hope to hit a
potency “home run”). Therefore, high SD values can also be
used as a diagnostic to systematically identify virtual
compounds with NBHs in discontinuous SAR regions.
■ DISCUSSION AND CONCLUSIONS
The SARM data structure was originally designed to organize
compound sets on the basis of core structures and substituents
and all possible structural relationships between cores. This was
accomplished through the systematic generation of A_MMS
and their organization in a matrix format. A characteristic
feature of SARMs is that they contain large numbers of virtual
compounds that represent as of yet unexplored core structure
and substituent combinations and hence offer suggestions for
compound design. However, the SARM data structure does not
enable a direct prioritization of such virtual compounds. Rather,
visual analysis of SARMs is required to study virtual
compounds. Therefore, we have developed a methodology to
predict novel active compounds from SARMs. The central idea
underlying this approach is the compound neighborhood
concept. For each virtual compound in SARMs, NBHs
exclusively consisting of known active compounds are system-
atically assessed. Virtual compounds can be ranked according to
numbers of such NBHs. Prioritization on this basis is akin to a
“guilt by association” approach, which assumes that the
likelihood of a virtual compound to be active increases with
the number of neighboring structural analogs. However, as
shown herein, one can go a step further and utilize the NBH
concept for potency predictions. These predictions are
facilitated by applying a Free-Wilson-like additivity principle
to individual neighborhoods. This leads to the prediction of the
potency of a virtual compound on the basis of differential core
and substituent contributions from active neighbors. Of course,
the approach is distinct from classical Free-Wilson analysis that
derives a mathematical model for the activity of a series of
analogs by additively accounting for contributions from all R-
groups. However, adapting the additivity principle essentially
limits NBH-based potency predictions to the applicability
domain of QSAR approaches, thus requiring the presence of
SAR continuity and the absence of activity cliffs and
cooperative SAR effects. A distinguishing feature of our
NBH-based prediction approach is that predictions over
multiple NBHs are prioritized. Then, one can assign confidence
to consistent predictions resulting in low SD values. As
demonstrated herein, accurate potency predictions were
obtained in such cases across different data sets, with prediction
accuracy further increasing with the number of qualifying
NBHs. Depending on the composition of NBHs, virtual
compounds with higher potency than known active neighbors
can be predicted, and these predictions can also be easily
prioritized. Moreover, potency predictions over multiple NBHs
can be used as a diagnostic for local SAR environments. For
example, predictions yielding high SD values are indicative of
discontinuous SAR regions surrounding virtual compounds in
which structurally analogous neighbors might have very
different potencies. Although these regions usually fall outside
the applicability domain of potency predictions employing an
additivity principle, they are nonetheless interesting for
compound design. This is the case because one might hope
to hit a potency “home run” in discontinuous regions that are
rich in NBHs, which are easily identified using the approach
introduced herein.
In conclusion, neighborhood-based matrix analysis and
potency predictions enable the prioritization of virtual
compound from SARMs and are thus anticipated to further
increase the attractiveness and utility of the SARM data
structure for medicinal chemistry applications.
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CHAPTER 5: SUMMARY
Summary
The study aimed to utilize compound neighborhoods present in SARMs in a
systematic manner to predict the potency of unknown virtual compounds. The
predictions are carried out by applying the Free-Wilson additivity principle
to individual neighborhoods. Each neighborhood represents a “mini-QSAR”
model. Predictions from multiple neighborhoods can be used as a diagnostic
for local SAR environments of virtual compounds. Virtual compounds with
consistent predictions map to continuous SAR regions and those with inconsis-
tent predictions map to the discontinuous SAR regions. Compounds that map
to continuous SAR region are predicted with high accuracy, whereas those that
map to the discontinuous SAR region fall outside the applicability domain of
this method. The neighborhood-based potency predictions enable the prioriti-
zation of virtual compounds from SARMs. My contribution to this study has
been the design, implementation and the analysis of the prediction methodol-
ogy.
The method reported herein is useful for hit-to-lead or lead optimization
data sets where explicit potency values are available. However, the methodology
is not optimal for data sets where approximate potency values are available, for
example, in screening sets. In the next study in Chapter 6, a novel conditional
probability-based prediction methodology is introduced to help prioritize active
virtual compounds from screening sets.
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Chapter 6
Hit Expansion from Screening
Data Based upon Conditional
Probabilities of Activity Derived
from SAR Matrices
Introduction
Advances in high-throughput screening (HTS) technology and combinatorial
chemistry have led to the fast accumulation of large amounts of activity data
for chemical compounds.5 With the screening results of a subset of a library at
hand, different chemoinformatics approaches can be utilized to expand the num-
ber of compounds and chemotypes around the primary hits. Approaches such
as nearest-neighbor search6 or machine-learning (ML) methods7 have gained
popularity. However, successful hit expansion approaches must ultimately find
a balance between mathematical complexity and chemical interpretability.
A novel methodology for hit expansion using SAR matrices is introduced
in this study. The method is especially suited for raw screening data and is
conceptually different from the QSAR-like approach discussed in the previous
Chapter. It derives conditional probabilities of activity of individual cores and
substituents from the activity information of compounds in SARMs. The per-
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formance of the newly designed SARM-based method is compared with state-
of-the-art machine learning methods.
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1 Introduction
Organizing sets of active compounds according to structur-
al criteria is a pre-requisite for the exploration of structure-
activity relationships (SARs). Popular approaches attempt to
decompose compound series into core structures and sub-
stituents by applying the scaffold concept[1] or by consider-
ing reaction information such as for the generation of stan-
dard R-group tables. While R-group tables are limited to
the representation of individual series, scaffold-based or-
ganization schemes can represent structurally diverse sets
of active compounds and are often supported by graphical
representation techniques.[1–3] Another powerful approach
for systematically organizing large compound data sets and
exploring SARs is the matched molecular pair (MMP) con-
cept.[4,5] An MMP is defined as a pair of compounds that
differ only by a structural change at a single site, which cor-
responds to the exchange of a pair of substructures.[4,5] Ac-
cordingly, changes in the activity of structurally related
compounds can be directly associated with a well-defined
structural modification.[5] MMPs can be algorithmically gen-
erated in a computationally efficient manner.[6] For SAR
analysis, matching molecular series (MMS)[7] have been in-
troduced as an extension of the MMP concept. An MMS is
defined as a series of compounds that only differ by chemi-
cal changes at a single site. Hence, MMS generated for
a compound data set include available analog series.[7]
The structure-activity relationship matrix (SARM) has
been introduced as a data structure to systematically or-
ganize large compound data sets on the basis of MMS and
identify SAR-informative compound series.[8] SARMs extract
all possible structural relationships between compound
series from data sets of any source and degree of heteroge-
neity. In addition to data set compounds forming MMS,
SARMs contain an abundance of new (virtual) compounds
that represent as of yet unexplored core-substituent combi-
nations and often new chemistry (because systematically
derived fragments from different compounds are com-
bined). These virtual compounds can be rationalized to rep-
resent a chemical space envelope around a given data set
and provide immediate suggestions for compound design.
Therefore, one would like to prioritize analogs, preferably
on the basis of activity predictions taking known activity in-
formation from existing data set compounds into account.
The computational prediction of new compounds on the
basis of series information is typically attempted by the ap-
plication of quantitative SAR (QSAR) approaches.[9,10] QSAR
derives mathematical models using molecular descriptors
that relate compound structure and properties to biological
activity and predict the effects of chemical substitutions on
activity. On this basis, new analogs can be predicted to
complement existing series and further improve activity.[10]
Because SARMs contain both data set compounds with
known activity and virtual compounds, matrix neighbor-
hoods of virtual compounds that exclusively consist of
known active compounds can be systematically identified
and neighborhood information can be used for activity pre-
diction.[11] In SARMs, compounds are represented as core-
substituent combinations. Therefore, the activity of virtual
Abstract : A new methodology for activity prediction of
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compounds can be predicted from core and substituent
contributions of known actives forming their neighbor-
hoods on the basis of Free-Wilson additivity principles,[12,13]
which represents one of the classical QSAR approaches. Ac-
cordingly, a ‘mini Free-Wilson model’ was built for each
qualifying SARM neighborhood of a given virtual com-
pound to predict its activity.[11] Virtual compounds often
have multiple qualifying neighborhoods in SARMs, which
makes it possible to assess the consistency of activity pre-
dictions.
Local Free-Wilson models introduced for SARM predic-
tions require numerical activity values as input such as ex-
plicit IC50 or Ki values. Hence, they are best applied to hit-
to-lead or lead optimization data sets. However, a major
limitation of QSAR models including SARM-based Free
Wilson models is that they are only applicable to com-
pound series representing continuous SARs, i.e. , when
structural modifications lead to gradual (and additive)
changes in activity.[14] By contrast, the presence of SAR dis-
continuity (including activity cliffs) falls outside the applica-
bility domain of standard QSAR modeling.[14,15] The pres-
ence of inconsistent activity predictions over multiple
neighborhoods of a given virtual compound in SARMs is an
indicator of SAR discontinuity in compound neighborhoods
and such predictions are thus eliminated from further con-
sideration.[11] Despite these general QSAR limitations,
a strength of the SARM approach is that it provides many
virtual candidates to further expand any given data set,
which is a consequence of the underlying MMS-based
structural organization. Therefore, it should be attractive to
explore alternative activity prediction schemes.
We have aimed to develop a conceptually different, non-
QSAR-like prediction approach that should be applicable to
all SAR environments. Such an approach would enable
matrix-based activity predictions for virtual compounds
originating from data sets in which SARs have not been
characterized in detail or in which only limited SAR infor-
mation is available such as biological screening data.
Herein we introduce a novel probability-based approach
for qualitative activity predictions that is generally applica-
ble to virtual candidate compounds, irrespective of their
SAR features. We show that the methodology is suitable for
the prediction of active compounds from screening data,
a task generally referred to as hit expansion.
2 Concepts and Methods
2.1 SAR Matrix Generation
SARMs are 2D matrices generated by subjecting com-
pounds to dual-step MMP fragmentation,[8] for which we
use an in-house implementation of the efficient MMP algo-
rithm by Hussain and Rea.[6] In the first step, data set com-
pounds are systematically fragmented at one, two, or three
exocyclic single bonds. The resulting larger fragment (core)
is stored in an index table as a key and the smaller frag-
ment(s) (substituents) as the corresponding value(s). In the
second step, the cores in the index table are subjected to
an additional round of fragmentation. The resulting frag-
ments are stored in a new index table with the larger frag-
ment representing the key, as before. Hence, this dual frag-
mentation scheme further extends the MMS concept[7] by
identifying all compound series having structurally related
cores termed ‘structurally analogous MMS’ (A_MMS).[8] This
process is illustrated in Figure 1. Three model series are
shown, each of which contains a common core structure
and differs at a single site. When the cores of these series
are subjected to a second round of fragmentation, core
MMP relationships are identified because these core struc-
tures only differ at a single site. Hence, series 1, 2, and 3
form A_MMS, which are represented in a unique SARM. As
illustrated in Figure 1, the SARM consists of compound
series that are structurally analogous. Each row in the
matrix contains an individual series and each cell represents
an individual compound (i.e. , a unique combination of
a key and value fragment). The series comprising a SARM
typically have overlapping yet distinct sets of substituents,
giving rise to combinations of filled cells representing ‘real’
data set compounds and empty cells representing virtual
compounds (i.e. , key-value combinations that have not yet
been explored). Cells corresponding to data set compounds
are annotated with their activity information using a color
code. In Figure 1, cells are colored red if they are inactive in
a given assay and green if they are active. Alternatively,
a continuous color spectrum can be used to represent rela-
tive activities.[11]
Typically, large compound data sets (including screening
data) yield many MMPs, MMS, and SARMs. In our experi-
ence, the number of MMPs obtained from large data sets,
including structurally heterogeneous sets, is not a limiting
factor for the SARM approach. SARMs capture all possible
core structure relationships contained in a given set and
represent all A_MMS. A given real or virtual compound
might participate in different A_MMS and hence occur in
different SARMs. It should also be noted that the majority
of SARMs (but not all SARMs) are incomplete from the
point of view that they consist of both data set and virtual
compounds, which provides the basis for compound
design and activity prediction.
2.2 Matrix-Based Probability of Activity
The assignment of SARM-based probabilities of activity to
virtual compounds is a central aspect of the new prediction
methodology. In SARMs according to Figure 1, all data set
compounds either belong to the active or the inactive class.
Hence, we base our considerations upon a binary classifica-
tion of assay activity.
Given the distribution of individual cores c and values v
in active and inactive compounds, we can derive respective
conditional probabilities for the classes y. Class contributions
of cores and values are assumed to be dependent on each
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other because compounds in a matrix are represented as
a combination of individual cores and values. To account
for this dependence, weights based upon initially deter-
mined probabilities are assigned to compounds in order to
calculate class contributions for each core and value. The
class probabilities of a virtual compound are then derived
by combining the contributions of its core and value, and
the compound is predicted to be active or inactive on the
basis of these probabilities. The calculation steps for the ac-
tivity assignment and classification method are further de-
scribed below and illustrated for a model SARM in Figure 2.
2.2.1 Core and Value Class Probabilities
In the first step, the class probability for each core and
value in a given matrix is calculated. Accordingly, P(y jc)
and P(y jv) are the conditional probabilities that describe
how likely it is to observe a given specific class y2{active,
inactive} for a core c and a value v, respectively. If c(x), v(x),
y(x) are the core, value, and class of a given compound x,
we can express the conditional class probabilities as the
fraction of compounds with a core c or value v and class y
over all compounds containing this core or value:
P yjcð Þ ¼
P
x 1 c
xð Þ ¼ c 1 y xð Þ ¼ y 
P
x 1 c xð Þ ¼ cð Þ
ð1Þ
Figure 1. SAR matrix. Three model compound series (1, 2, and 3) containing three compounds each (A–C, D–F, and G–I) are shown with
their activity annotations (inactive, red; active, green). Compounds in a series share a common core structure and differ by substitutions at
a single site (highlighted in gray). The three series contain structurally related cores. Substructure differences between cores are highlight-
ed in red. The SAR matrix is generated by combining all analog series with structurally related cores. Rows and columns represent com-
pounds that share the same core and substituent, respectively. In each cell, the combination of a core and a substituent defines a unique
compound. Compounds present in the data set are indicated by filled cells that are color-coded according to activity. In addition, empty
cells represent virtual compounds (core-substituent combinations).
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P yjvð Þ ¼
P
x 1 v
xð Þ ¼ v 1 y xð Þ ¼ y 
P
x 1 v xð Þ ¼ vð Þ
ð2Þ
Here, 1(a=b) is a function that returns 1 if a=b and 0
otherwise. Core and value class probabilities are given in
Figure 2a for the three core (c1–c3) and four value frag-
ments (v1–v4) of the SARM in Figure 1. For the core c1, the
class probability of activity (0.67) is higher than of inactivity
(0.33), whereas for value v3, the class probabilities are
equal.
2.2.2 Core- and Value-Weighted Matrices
Inverse class probabilities are used as core weights and
value weights of data set compounds:
wc xð Þ ¼ P y xð Þjc xð Þ
 1¼
P
x 1 c
xð Þ ¼ c 
P
x 1 c xð Þ ¼ cð Þ1 y xð Þ ¼ yð Þ
ð3Þ
wv xð Þ ¼ P y xð Þjv xð Þ
 1¼
P
x 1 v
xð Þ ¼ v 
P
x 1 v xð Þ ¼ vð Þ1 y xð Þ ¼ yð Þ
ð4Þ
Two weighted matrices are derived from the inverse
class probabilities of the cores and values and are referred
to as the core-weighted and value-weighted matrix, respec-
tively. In case of the core-weighted matrix, the inverse class
probabilities of the cores are mapped to the compounds
that represent the corresponding core and class. In Fig-
ure 2b, a core-weighted matrix is shown in which the in-
verse probability for the inactive and active class for core
c1 is 3.0 and 1.5, respectively. Hence, the inactive com-
pound C (Figure 2a) is assigned a weight of 3.0, and the
Figure 2. SARM classification. For the model SARM with three cores (c1–c3) and four values (v1–v4), represented according to Figure 1,
step-wise class probability calculations are illustrated. (a) Initial class probabilities for the cores and values are reported. (b) shows the core-
weighted matrix. Compounds are assigned weights depending on the inverse core class probabilities. Value class contributions calculated
from the weights of each value are shown. (c) shows the value-weighted matrix. Compounds are assigned weights depending on the in-
verse value class probabilities. Core class contributions calculated from the weights of each core are reported. (d) Updated value and core
class probabilities are derived from the matrices in (b) and (c), respectively. Activity probability (px) values are reported for virtual com-
pounds and the corresponding cells are color-coded red (predicted inactivity) or green (predicted activity) according to the classification
scheme detailed in the text.
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active compounds A and B are each assigned a weight of
1.5. Accordingly, the less frequently observed class is as-
signed a higher weight, as further rationalized below. For
virtual compounds (empty cells), the class is unknown and
no weight is assigned. Similarly, inverse class probabilities
of values are mapped to compounds that contain the cor-
responding values and belong to the corresponding class,
thus producing a value-weighted matrix as shown in Fig-
ure 2c.
2.2.3 Core and Value Class Contributions
From the weighted matrices, class contributions are calcu-
lated. The core-weighted matrix is used for deriving the
value class contributions and the value-weighted matrix for
deriving the core class contributions. This rationalizes the
calculation of weights from the previous step: the less fre-
quently observed class for a core is assigned a higher
weight, which leads to a stronger class contribution of the
corresponding value of a compound. In the case of core c2
in Figure 2b, a weight of 3.0 for compound D (Figure 2a)
given by value v1 indicates that the compound is predomi-
nantly inactive due to the influence of value v1, more so
than due to the influence of core c2. Thus, for calculating
the class contributions for value v1, individual core weights
of compounds represented by value v1 are considered:
cv yð Þ ¼
aþPx wc xð Þ1 v xð Þ ¼ v
 
1 y xð Þ ¼ y 
2aþPx 1 v xð Þ ¼ vð Þ
ð5Þ
Similarly, individual core contributions can be calculated
by using the weights from the value-weighted matrix:
cc yð Þ ¼
aþPx wv xð Þ1 c xð Þ ¼ c
 
1 y xð Þ ¼ y 
2aþPx 1 c xð Þ ¼ cð Þ
ð6Þ
The smoothing parameter a is used to prevent zero
probabilities in cases where there is no compound with
a certain core or value for a class. For example, this is the
case for value v2 in Figure 2 that does not represent inac-
tive compounds. Without application of this smoothing
factor, the value class contribution for v2 and the inactive
class would be unlikely for a limited sample size:
cv2 inactiveð Þ ¼
P
x wc xð Þ1 v xð Þ ¼ v2
 
1 y xð Þ ¼ inactive 
P
x 1 v xð Þ ¼ v2ð Þ ¼
0
2
Therefore, Laplacian smoothing is applied to account for
the possibility that there might be a small number of inac-
tive instances with value v2 that are not used for training.
From the class contributions, the corresponding updated
core class and value class probabilities P’(y jc) and P’(y jv) are
obtained through normalization:
P0 yjcð Þ ¼ cc yð ÞP
y^ cc y^ð Þ ð7Þ
P0 yjvð Þ ¼ cv yð ÞP
y^ cv y^ð Þ ð8Þ
Individual value and core class contributions are given in
Figure 2b and c, respectively, and the corresponding updat-
ed class probabilities are reported in Figure 2d.
2.2.4 Combined Class Probabilities
Finally, to predict the activity probability px of a virtual com-
pound x, the corresponding updated core and value class
probabilities are combined:
px ¼
P0 yjc xð Þ P0 yjv xð Þ 
P
y^ P0 y^jc xð Þð ÞP0 y^jv xð Þð Þ
ð9Þ
The resulting value ranges from 0 to 1 and an increasing
value reflects the increasing probability for a compound to
be active. Calculated values for predicting the activity state
of virtual SARM compounds are given in Figure 2d. Two of
three virtual compounds with values of 0.66 and 0.99 are
predicted to be active, whereas one (0.13) is predicted to
be inactive.
2.2.5 Exemplary Calculations
As an example for the calculations summarized in Figure 2,
let us consider the virtual compound consisting of core c3
and value v1. Its core is shared by compounds G, H, and I
and its value by compounds A and D. Consequently, the
contributions of these compounds are taken into account
for activity prediction.
First, activity probabilities are calculated for all participat-
ing cores and values, i.e. , not only for c3 and v1, but also
c1, c2, v2, v3, and v4, because they are present in com-
pounds containing c3 or v1. These frequency-based proba-
bility calculations are summarized in Figure 2a. The result-
ing probabilities suggest that our virtual compound is two
times more likely to be inactive than active due to the pres-
ence of core c3 and that value v1 does not convey activity
information. These initial estimates are then further refined
(updated) by taking information of all compounds in the
SARM into account.
To arrive at an updated probability of core activity, the
value-weighted matrix is derived. Here, the value weights
of compounds G, H, and I, which share core c3 with the vir-
tual compound, are taken into consideration. These value
weights are calculated according to Equation 4 and give
the contribution of each value to a class. For example, com-
pound G has a value weight of 1, because only active com-
pounds contain this value. Furthermore, compound I has
a value weight of 1.5 because it belongs to the majority
class (inactive) of compounds with value v4. Finally, com-
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pound H has the highest value weight of 2.0 because its
class (inactive) is observed equally frequent as the active
class. Hence, the value weight of a given compound is in-
creasing with the number of compounds belonging to the
other class. From compounds G-I, we can calculate the core
class contributions for c3 according to Equation 6 with
a smoothing factor of a=0.1
cc3 activeð Þ ¼
0:1þ 1:0
0:2þ 3 ¼ 0:34
cc3 inactiveð Þ ¼
0:1þ 2:0þ 1:5
0:2þ 3 ¼ 1:12
Through normalization using Equation 7, we arrive at the
updated core class probabilities of 0.23 and 0.76, respec-
tively. By weighting compounds H and I higher than G, the
core contribution to inactivity was increased.
Analogously, to calculate the class contributions for value
v1, the core weights of compounds A and D are used. A is
active and belongs to the majority class of c1 and hence
has a lower weight than D, which is inactive and belongs
to the minority class of c2. Consequently, the inactive com-
pound D influences the class probability of v1 more than
the active compound A, which leads to an increased proba-
bility of inactivity. The underlying idea is that compound D
is unlikely to be inactive because of its core; hence, its
value should be responsible for inactivity.
2.3 Activity-Based Classification
2.3.1 Concept
SARMs were generated for compound data sets from indi-
vidual screening assays taken from PubChem[16] (see
below). For each classification trial, 20% of the SARM com-
pounds were randomly selected as test compounds. These
test compounds were converted into virtual compounds
for predictions. The training compounds (80%) were used
to calculate core and value class probabilities of individual
matrices. A test compound can appear in different matrices.
In each matrix, it represents a unique combination of core
and value fragment. Thus, a test compound can be as-
signed multiple matrix-dependent px values. Therefore,
a mean activity probability value p^x was assigned to a test
compound contained in multiple SARMs. Test compounds
for which no training compounds with corresponding core
and value fragments were available (due to the random re-
moval of test instances from SARMs) were omitted. Each
qualifying test compound was assigned to one of three dif-
ferent categories (as further discussed below) based on the
calculated mean activity probability values: inactive, p^x<
0.5; inconclusive, p^x=0.5; active, p^x>0.5.
2.3.2 Calculations
For each data set, 10 different trials with randomly assem-
bled training and test sets were carried out. Routines to
generate SARMs were implemented with the aid of the
OpenEye chemistry toolkit[17] and classification routines
were implemented in Java. For Laplacian smoothing, we
consistently used a factor of a=0.1.
2.4 SARM Selection
For probability-based activity predictions, SARMs are pre-
ferred that have a high compound density and overlap be-
tween corresponding values (columns) in different A_MMS
(rows). Therefore, a matrix overlap measure is applied. For
a given SARM, matrix overlap is determined as the average
of all row overlap (RO) values. For individual columns in
SARMs, RO is calculated as
RO ¼ nc  1
#rows 1 ð10Þ
Here nc corresponds to the number of data set com-
pounds present in each column. RO yields a numerical
score between 0 (no overlap) and 1 (complete overlap).
Thus, an RO of 0 for each column of a matrix will result in
the matrix overlap score of 0, reflecting a mutually exclu-
sive nature of the substitution patterns among the A_MMS
comprising the SARM, whereas an RO of 1 for each column
will result in the matrix overlap of 1, reflecting the presence
of A_MMS with identical substitution patterns.
Figure 3 reports the distribution of SARMs with a matrix
overlap score of <0.5 (dark blue) and 0.5 (light blue) for
different data sets. For our classifications, only matrices that
had an overlap score 0.5 were preselected.
Furthermore, qualifying SARMs were assigned to three
different categories depending on the class composition
(CC) of the compounds: exclusively inactive, SARMs only
containing inactive compounds; mixed, SARMs containing
both active and inactive compounds (with varying ratio) ;
exclusively active, SARMs containing only active com-
pounds.
Figure 4 reports the distribution of SARMs with a CC for
the different assay data sets over these three states.
The set of qualifying SARMs (matrix overlap score 0.5)
is in the following referred to as a-SARMs. In addition,
a subset of qualifying SARMs was generated for model
building and predictions in which exclusively active and ex-
clusively inactive SARMs were omitted. This subset was gen-
erated to avoid potential bias of class probability calcula-
tions by these exclusive CC categories and is referred to as
b-SARMs. The SARM subset selection is illustrated in
Figure 5.
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2.5 Assays
Nine different confirmatory bioassays were assembled from
PubChem. From each screening compound set, SARMs
were systematically generated and analyzed. Table 1 reports
the assay data sets, their composition, the total number of
SARMs, and the compounds comprising these SARMs.
Table 2 summarizes the number of a-SARMs and their com-
pound content, and Table 3 b-SARMs and their composi-
tion. SARM-based activity predictions and control calcula-
tions (see below) were carried out for both a-SARMs and b-
SARMs. It should be noted that only assays that resulted in
at least 50 SARMs comprising at least 100 compounds were
considered for SARM-based predictions. The nine selected
assays satisfied these criteria for both a-SARMs and b-
SARMs.
Figure 3. Matrix overlap distribution. Bar plots represent the distribution of matrix overlap scores below 0.5 (dark blue) and equal to or
greater than 0.5 (light blue) over all assays. For these scoring ranges, exemplary SARMs are shown on the right.
Figure 4. Class composition distribution. Bar plots represent the distribution of matrix compound class composition for ‘exclusively inac-
tive’ (maroon), ‘mixed’ (dark pink), and ‘exclusively active’ (light pink) types over all assays. For these composition types, exemplary SARMs
are shown on the right.
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These assays were pre-selected on the basis of MMS and
matrix generation to yield a significant number of overlap-
ping A_MMS and informative matrices that ensure statisti-
cally sound predictions. In prospective practical applica-
tions (for which no statistical validation is required), sparse-
ly populated matrices can also be used.
2.6 Control Calculations
To put the results of SARM-based activity prediction into
perspective, control calculations were carried out using
three state-of-the-art machine learning methods including
nave Bayesian classification (NB),[18] random forests (RF),[19]
and support vector machines (SVM).[20] NB and RF models
also produce probability scores while SVMs yield discrimi-
native models.
For all calculations, extended connectivity fingerprints
with bond diameter 4 (ECFP4)[21] were used as compound
descriptors. For NB, the Bernoulli formulation was applied
to account for the binary nature of the fingerprint descrip-
tors. In addition, SVM models were generated using the Ta-
nimoto kernel.[22] Furthermore, to account for the imbal-
ance of active and inactive training compounds in the dif-
ferent assay data sets (i.e. , more inactive compounds were
available), we applied sample weights inversely proportion-
al to the number of actives and inactives in the training
set, respectively. For each control method, 10 individual
trials were performed on the same training and test sets
used for SARM-based predictions. Implementations of the
freely available Python library scikit-learn[23] were used.
Figure 5. SARM selection. Selection criteria for a-SARM and b-
SARM (compound) subsets are summarized.
Table 1. PubChem assay data and SAR matrices. For each assay, the PubChem Assay ID (AID), the target name, the number (#) of total
compounds (cpds) in the assay, the number of SARMs, and the number of compounds covered by these SARMs (including inactives and ac-
tives) is reported.
AID Target # total cpds # SARMs # cpds # inactive # active
883 Cytochrome P450/2C9 7461 2808 3988 3210 778
884 Cytochrome P450/3A4 9685 3226 4952 2675 2277
885 Cytochrome P450/3A4 11982 4253 6475 6372 103
891 Cytochrome P450/2D6 7213 2782 3795 2920 875
899 Cytochrome P450/2C19 7547 2896 4064 2847 1217
915 Hypoxia-inducible factor 1 7647 2142 3749 3629 120
1770 CDC-like kinase 4 1126 1153 1126 794 332
1771 CDC-like kinase 4 1103 1138 1103 747 356
504865 USP1 protein 5764 1633 2551 2465 86
Table 3. Statistics for b-SARMs. For each assay, the number of se-
lected b-SARMs and the number of compounds contained in these
b-SARMs (including inactives and actives) is reported.
AID # b-SARM # cpds # inactive # active
883 620 2550 1980 570
884 687 2519 1013 1506
885 238 1954 1867 87
891 426 2315 1697 618
899 766 2650 1748 902
915 89 584 557 27
1770 97 680 485 195
1771 81 634 428 206
504865 151 953 901 52
Table 2. Statistics for a-SARMs. For each assay (indicated by AID
according to Table 1), the number of selected a-SARMs and the
number of compounds contained in these a-SARMs (including in-
actives and actives) is reported.
AID # a-SARM # cpds # inactive # active
883 1215 2889 2275 614
884 1089 2749 1101 1648
885 1828 3930 3843 87
891 1164 2567 1938 629
899 1265 2876 1944 932
915 771 2214 2183 31
1770 251 910 677 233
1771 215 865 610 255
504865 504 1454 1402 52
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As additional controls, we also carried out standard k-
nearest neighbor (k-NN) similarity search calculations (1-NN,
5-NN, and 10-NN) using fingerprints on a subset of assays.
The prediction accuracy of these k-NN search calculations
was consistently lower than of all machine learning and
SARM-based classification calculations. Therefore, the re-
sults of k-NN control calculations were not included in the
detailed comparison presented below.
2.7 Performance Measures
Average statistics were calculated over all 10 trials and
used for performance evaluation. The following per-
formance measures were applied:
Balanced accuracy ¼ BAC ¼ 0:5*TP
actives
þ 0:5*TN
inactives
F1 score ¼ 2*TP
2*TPþ FNþ FPþ IA
TP, TN, FP, and FP define the number of true positives,
true negatives, false positives, and false negatives, respec-
tively, and IA denotes the number of compounds that were
active but predicted to be inconclusive. In addition, area
under the receiver operating characteristic (ROC) curve
(ROC AUC) [24] values were also calculated as performance
measures.
The control calculations produce predictions for all com-
pounds including those that are inconclusive using the
SARM approach. Hence, the performance measures were
adjusted to classify inconclusive SARM predictions as false
(yielding a conservative estimate for the performance of
the SARM approach).
3 Results and Discussion
3.1 Study Design
SARMs provide a systematic MMS-based organization of
a compound data set and capture all possible structural re-
lationships between compound series. Because SARMs also
reveal all possible key-value combinations arising from sys-
tematic MMP fragmentation, they also provide many virtual
compounds for further exploration that expand the chemi-
cal space around a given compound set. Therefore, activity
predictions are highly desirable to prioritize virtual candi-
date compounds for synthesis. QSAR-like predictions are
feasible for virtual candidates with qualifying neighbor-
hoods on the basis of local Free-Wilson models[12] and are
particularly suited for hit-to-lead or other chemical optimi-
zation campaigns. However, these local QSAR models typi-
cally require the presence of advanced compound data
sets with significant SAR information content and are con-
fined to continuous SAR environments in SARMs and thus
not generally applicable.[11] Therefore, we have set out to
develop a conceptually distinct activity prediction method
that is generally applicable to data sets of any source, with
a particular focus on hit expansion from screening data, for
which QSAR-type approaches are not well applicable. Hit
expansion focuses on narrowly defined chemical space
around “activity islands” which can be well mapped using
SARMs. These considerations have led to the design of the
conditional probability-based SARM prediction approach
presented herein.
3.2 SARM Statistics
The number of SARMs generated for the nine assay data
sets (comprising 1103 to 6475 compounds) ranged from
1138 to 4253. Three assays (AID: 885, 915, and 504865) had
a strongly unbalanced class composition with significantly
fewer active than inactive compounds, as one would
expect from confirmatory screening data (Table 1). Some
assays were directed against the same target; for example,
AID 884 and 885 addressed cytochrome P450 3A4. These
two assays shared 9468 compounds but only 6067 com-
pounds had the same activity state (active/inactive) in both
the assays. This was also reflected by the activity distribu-
tion of SARM compounds from these two assays. SARMs of
AID 884 retained many more actives (2277) compared to
AID 885 (103). Furthermore, AID 1770 and 1771 reported
CDC-like kinase 4 inhibitors. In this case, different from the
P450 assays, there was significant overlap of active/inactive
compounds (1051).
The number of SARMs selected for model building and
prediction on the basis of matrix overlap scores ranged
from 215 to 1828 (Table 2). On average, pre-selected SARMs
retained 67% of the assayed compounds. Hence, although
screening sets are often diverse, SARMs detected many
MMS and structural relationships between data sets com-
pounds.
3.3 Prediction Accuracy
Activity predictions were systematically carried out on the
basis of pre-selected a-SARMs and their b-SARM subsets, as
detailed in the Methods section. We separately determined
the prediction accuracy for these sets.
3.3.1 a-SARMs
Average ROC AUC values obtained for a-SARM predictions
are reported in Table 4. Despite the highly variable class
composition of a-SARMs, our probability-based approach
accurately predicted active and inactive compounds with
ROC AUC values for SARM consistently above 90%.
3.3.2 b-SARMs
Compared to a-SARMs, the proportion of retained inactive
compounds was significantly reduced in b-SARMs, due to
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the removal of exclusively inactive matrices, whereas the
proportion of active compounds essentially remained con-
stant, despite the removal of exclusively active matrices.
Thus, b-SARMs further balanced the composition of learn-
ing and test sets. Table 5 reports the ROC AUC values ob-
tained for b-SARMs that were similar to those obtained for
a-SARMs (Table 4). Hence, the exclusion of exclusively
active/inactive matrices did not notably compromise aver-
age prediction accuracy across all assay data sets.
Table 6 reports the average percentage of active and in-
active compounds that predicted to be inconclusive on the
basis of a-SARMs and b-SARMs, which was consistently very
small and negligible.
3.4 Method Comparison
Given the perhaps surprisingly high performance of the
probability-based activity prediction approach, we com-
pared SARM-based calculations with state-of-the-art ma-
chine learning methods including NB, RF, and SVM using al-
ternative performance measures. In Tables 4 and 5, average
ROC AUC values of the control calculations are compared
to SARM-based predictions using the same training and
test sets. The comparison reveals that global prediction
performance of the SARM-based approach reached or ex-
ceeded performance levels of the machine learning meth-
ods. It should be noted that the SARM-approach uses
MMP-based compound representations, while the control
calculations were carried out using fingerprints. Different
compound representations compromise direct compari-
sons.
Since only limited numbers of active compounds were
available as test instances in unbalanced data sets, BAC
and F1 scores were also calculated as performance meas-
ures. Figure 6 shows that prediction performance in part
significantly differed for different assay data sets. Balanced
accuracy equally weights true positives and true negatives,
regardless of the composition of data sets, and accounts
for the fraction of individual test compounds that were cor-
rectly predicted. In Figure 6 (left), average balanced accura-
cy for individual assays was highest for SVM when a-SARMs
were considered. Balanced accuracy for SARM-based pre-
dictions was comparably high (>80%) for data sets with
balanced class composition but lower (~60%) for unbal-
anced data sets. Both NB and SVM classifiers reached
higher performance than RF and SARM-based predictions
for unbalanced sets. F1 scores were also compared, which
account for the fraction of true positive, but not true nega-
tive predictions. In this case, the performance was compa-
rable for all methods. Similar trends were observed for
average BAC and F1 scores across balanced and unbal-
anced a-SARMs and b-SARMs. For example, average BAC
and F1 scores for AID 884 and 885 varied for a-SARM and
b-SARM sets. For AID 884, for which much larger numbers
of active training compounds were available than for AID
885, higher F1 and BAC scores were observed for all meth-
ods (except BAC values for SVM and NB). By contrast, BAC
and F1 scores for AID 1770 and 1771 were comparable,
consistent with their large compound overlap, as discussed
above.
3.5 Prediction Visualization
In Figure 7, an exemplary SARM-based prediction is shown
for the USP1 assay (AID: 504865). The SARM contains seven
Table 4. ROC AUC values for a-SARMs. For each assay, average
ROC AUC values (and standard deviations) from 10 trials for SARM,
NB, RF, and SVM predictions of compounds contained in a-SARMs
are reported.
AID SARM NB RF SVM
883 0.94 (0.01) 0.90 (0.01) 0.93 (0.01) 0.94 (0.02)
884 0.95 (0.01) 0.88 (0.01) 0.95 (0.01) 0.96 (0.01)
885 0.97 (0.02) 0.94 (0.02) 0.93 (0.03) 0.98 (0.02)
891 0.94 (0.01) 0.91 (0.01) 0.93 (0.01) 0.95 (0.01)
899 0.92 (0.01) 0.87 (0.02) 0.92 (0.01) 0.93 (0.01)
915 0.92 (0.05) 0.93 (0.02) 0.83 (0.07) 0.96 (0.02)
1770 0.97 (0.02) 0.92 (0.02) 0.97 (0.02) 0.97 (0.02)
1771 0.98 (0.01) 0.94 (0.01) 0.98 (0.01) 0.99 (0.01)
504865 0.92 (0.04) 0.93 (0.06) 0.88 (0.08) 0.95 (0.03)
Table 5. ROC AUC values for b-SARMs. For each assay, average
ROC AUC values (and standard deviations) from 10 trials for SARM,
NB, RF, and SVM predictions of compounds contained in b-SARMs
are reported.
AID SARM NB RF SVM
883 0.92 (0.02) 0.87 (0.02) 0.91 (0.02) 0.93 (0.01)
884 0.95 (0.01) 0.88 (0.02) 0.94 (0.01) 0.96 (0.01)
885 0.96 (0.02) 0.92 (0.03) 0.94 (0.04) 0.97 (0.02)
891 0.94 (0.01) 0.90 (0.01) 0.93 (0.01) 0.94 (0.01)
899 0.92 (0.01) 0.86 (0.02) 0.92 (0.01) 0.93 (0.01)
915 0.83 (0.07) 0.79 (0.13) 0.81 (0.08) 0.85 (0.09)
1770 0.95 (0.02) 0.91 (0.02) 0.96 (0.03) 0.96 (0.01)
1771 0.95 (0.03) 0.93 (0.03) 0.96 (0.02) 0.98 (0.02)
504865 0.87 (0.05) 0.89 (0.08) 0.86 (0.08) 0.91 (0.06)
Table 6. Inconclusive SARM predictions. For each assay, the aver-
age percentage of active and inactive compounds yielding incon-
clusive SARM predictions is reported for the a-SARM and b-SARM
subsets.
AID a-SARM b-SARM
% active % inactive % active % inactive
883 0.0 0.08 0.37 0.18
884 0.10 0.13 0.10 0.0
885 0.0 0.0 0.0 1.17
891 0.08 0.52 0.26 0.51
899 0.22 0.11 0.3 0.06
915 0.0 7.0 4.0 10.6
1770 0.25 1.5 0.27 1.79
1771 0.0 0.90 1.5 2.18
504865 0.0 2.0 0.0 0.0
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structurally related cores and 14 value fragments, which
form 60 analogs (filled cells), 12 of which were randomly
selected as test instances. In addition, the SARM contains
38 virtual compounds (that would be prediction targets in
practical applications). Individual calculated px values are
given for each test compound. All inactive test compounds
were correctly predicted with px values ranging from 0.0 to
0.07. In addition, one of two active test compounds was
correctly predicted with a px of 0.72, whereas the other was
assigned a px of 0.03, which yielded a false negative predic-
tion. The corresponding updated core and value class con-
tributions for the two active test compounds are also
given. The example illustrates the potential of the newly in-
troduced probability-based prediction approach for hit ex-
pansion on the basis of SARMs.
4 Conclusions
Herein we have introduced a new methodology for com-
pound activity prediction that derives conditional probabili-
ties of activity from compounds in SARMs and is readily ap-
plicable to predict the activity of virtual candidate com-
pounds. The development of the conditional probability-
based approach generalizes activity predictions for virtual
compounds and is particularly suited for hit expansion. As
such, it complements QSAR-type predictions at later stages
of compound optimization efforts. The methodological
concept of the conditional probability approach has been
described in detail. Furthermore, its predictive performance
on different screening data sets has been assessed and
found to be generally high and comparable to state-of-the-
art machine learning approaches (which are mostly used
for other compound classification applications). The SARM-
based activity prediction method is interpretable and much
more intuitive than, for example, support vector machines,
yet predicts active compounds with comparable accuracy.
Its major goal is the prioritization of virtual candidate com-
pounds in SARMs for hit expansion. The reliable prediction
of inactive and active virtual compounds from SARMs, re-
gardless of the presence of SAR continuity or discontinuity,
is considered a substantial advance for practical applica-
tions.
Figure 6. Prediction performance for SARM subsets. Average F1 scores (top) and balanced accuracy (BAC, bottom) are reported for SARM,
NB, RF, and SVM predictions on all assays for (a) a-SARM and (b) b-SARM compound subsets. Vertical lines give standard deviations over
multiple predictions. Assay IDs are provided according to Table 1.
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CHAPTER 6: SUMMARY
Summary
The methodology introduced here further expands the utility of the SAR matrix
data structure in prioritizing and predicting virtual compounds from screening
sets. The methodological concept of the conditional probability utilizes the
assumption that either the core, substituent, or their combination might be
responsible for the (in)activity. The method performs at par with machine
learning methods and has low computational complexity. My contribution to
this study has been the design, implementation and analysis of the SARM-based
prediction approach.
In this study, benchmark calculations of the SARM-based probability method
on publicly available assays are reported. The first prospective application of
this approach on a raw screening set is reported in the next Chapter 7.
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Chapter 7
Prospective Compound Design
using the SAR Matrix-Derived
Conditional Probabilities of
Activity
Introduction
A collaboration study with PRISM Biolab Corporation is presented in this
Chapter. A library of approximately 10,000 compounds is analyzed using the
SARMs to identify novel compounds. The compounds represent alpha heli-
cal turn mimetics and comprise of well-defined scaffold-substituent patterns.
These compounds were screened once at a single concentration to search for
new inhibitors of the Wnt/β-catenin pathway.8
Prediction methods reported so far in the dissertation provided opportu-
nities to prioritize the resulting virtual compounds. However, in this case,
the NBH-based prediction approach (Chapter 5) is difficult to utilize for hit
expansion because of the approximate nature of activity annotations obtained
from raw screening data. Therefore, the conditional probability-based approach
(Chapter 6), which involves the binary classification of compounds into actives
and inactives, is utilized. This study is the first prospective application of the
107
CHAPTER 7: INTRODUCTION
SARM-derived probabilities for prediction and might be of interest for medici-
nal chemistry applications.
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Abstract
In a previous Method Article, we have presented the ‘Structure-Activity
Relationship (SAR) Matrix’ (SARM) approach. The SARM methodology is
designed to systematically extract structurally related compound series from
screening or chemical optimization data and organize these series and
associated SAR information in matrices reminiscent of R-group tables. SARM
calculations also yield many virtual candidate compounds that form a “chemical
space envelope” around related series. To further extend the SARM approach,
different methods are developed to predict the activity of virtual compounds. In
this follow-up contribution, we describe an activity prediction method that
derives conditional probabilities of activity from SARMs and report
representative results of first prospective applications of this approach.
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Introduction
In recent years, graphical methods have substantially expanded the 
medicinal chemistry repertoire for analyzing Structure-Activity 
Relationships (SARs)1,2. The development of computational tech-
niques to visualize SAR patterns and identify key compounds has in 
part been catalyzed by increasing volumes and complexity of activ-
ity data in medicinal chemistry. Going beyond a purely descriptive 
nature of graphical SAR exploration, as exemplified by activity 
landscape representations1, the SAR Matrix (SARM) approach3 
was conceptualized to combine large-scale graphical SAR analysis 
and compound design. SARM calculations generate many virtual 
compounds (VCs) that populate chemical space around structurally 
related series. In order to prioritize virtual candidate compounds 
from SARMs in a target/assay-specific manner, activity prediction 
methods have been developed including local Quantitative SAR 
(QSAR) models utilizing compound neighborhood information in 
SARMs4 and an approach that derives conditional probabilities of 
activity from SARMs5.
In a previous Method Article6, the SARM methodology and exten-
sions have been described including matrix-based QSAR4 and navi-
gation of multi-target activity spaces7. In this follow-up contribution, 
we focus on a conditional probability-based approach to activity 
prediction, which is distinct from QSAR analysis, and report results 
of first prospective applications. While we are currently unable to 
disclose the structures of active compounds (due to patent issues 
of PRISM Biolab Corporation), the prediction statistics and exem-
plary results we report for an actual drug discovery project should 
be helpful to put SARM-based predictions into perspective, beyond 
            Amendments from Version 1
We thank all four reviewers for their comments. In our revision, the 
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Georgia B. McGaughey:
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via a separate open access data deposition. In addition, further 
methodological explanations have been added to the revision and 
the similarity of library and virtual candidate compounds has been 
briefly discussed.
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computational benchmarking, and might spark the interest of prac-
titioners in this field.
Methods
Since details of the SARM methodology and matrix-based QSAR 
modeling have been presented in the accompanying article6, we ini-
tially provide only brief summaries of these methods, followed by a 
detailed description of the conditional probability approach.
SAR matrices
To generate SARMs compounds are subjected to a systematic two-
step fragmentation procedure yielding matched molecular pairs 
(MMPs)8. An MMP is defined as a pair of compounds that only 
differ at a single site. In the first step, compounds are fragmented 
into core structures and substituents. In the second step, resulting 
core structures are subjected to fragmentation. This two-step frag-
mentation protocol identifies series of compounds with related core 
structures (forming “core MMPs”). Series of compounds with cores 
forming MMP relationships are organized in individual SARMs, as 
illustrated in Figure 1. Each matrix cell defines a unique combination 
of a core and substituent (reminiscent of yet distinct from R-group 
tables). Following MMP terminology, the core is called key fragment 
and the substituent value fragment8. Each filled cell represents an 
actual compound color-coded by activity or potency and each empty 
cell a VC representing a previously unexplored core-substituent 
(key-value) combination. Accordingly, VCs are thought to generate 
a “chemical  space envelope” around structurally related compound 
series. Depending on the structural relationships that are present 
within a given compound set, varying numbers of SARMs are 
obtained that systematically organize available analog series and 
provide many VCs for further consideration. The more similar data set 
compounds are to each other, the more SARMs are typically obtained.
Matrix-based local QSAR models
A compound neighborhood (NBH) approach was developed for 
potency prediction of VCs based on known potencies of structural 
analogs4, as illustrated in Figure 2. A qualifying NBH consists of 
two known active compounds that contain the key and value frag-
ment of a given VC, respectively (D and G in Figure 2a), and a 
third active compound (E) that consists of the key of D and value 
of G. The potency of a VC can then be predicted from its neigh-
bors by applying the additivity assumption underlying Free-Wilson 
analysis9 using the equation shown in Figure 2a. For a given VC, all 
qualifying NBHs are identified across all SARMs, as illustrated in 
Figure 2b, and for each NBH, an individual potency prediction is 
carried out using a local “mini-QSAR” model. The average potency 
over all NBHs is then calculated to yield the final prediction.
The NBH approach is based upon numerical values and thus 
well suited for potency prediction during compound optimiza-
tion considering multiple analog series. Principal limitations of 
QSAR modeling also apply to the NBH methodology, given its 
Free-Wilson foundation. Hence, meaningful potency predictions 
can only be expected in the presence of SAR continuity (when 
small structural changes are accompanied by gradual changes in 
potency). By contrast, SARMs capturing discontinuous SARs or 
activity cliffs10 fall outside the QSAR applicability domain. Because 
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Figure 2. Neighborhood-based activity prediction. (a) A NBH of virtual compound X is marked in blue in a model SARM and compounds 
forming this NBH are displayed. Compounds D and G share the same substituents and core with X, respectively, and the third neighbor E 
consists of the core of D and substituent of G. At the lower left, the equation to predict the potency of X from the values of D, E, and G is 
shown. (b) The process of NBH mining is illustrated. For X, the set of all qualifying NBHs (marked in blue) in a given SARM are identified and 
potency values are predicted for individual NBHs (indicated by color-coded squares). “act” stands for activity (in this case, numerical potency 
values are used).
Figure 1. SAR matrix. A schematic representation of a SARM is shown. Compound fragmentation (indicated by thick lines in matrix cells) 
yields three analog series with structurally related cores (keys). Each series consists of analogs that share a core and differ by a single 
substituent (value, blue). Structural differences between the cores of the three series are highlighted in red. Each SARM combines all analog 
series with structurally related cores available in a compound set. Rows and columns represent compounds sharing the same core and 
substituent, respectively. In each cell, the combination of a core and a substituent defines a unique molecular structure. Compounds present 
in the data set are represented by filled cells that are color-coded according to activity. In addition, empty cells represent virtual compounds 
(i.e., previously unexplored key-value combinations resulting from MMP fragmentation).
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potency predictions are carried out over multiple NBHs in dif-
ferent SARMs, standard deviations of predictions provide a sim-
ple yet effective indicator of prediction reliability. High and low 
standard deviations indicate the presence of SAR discontinuity 
and continuity, respectively, for compound subsets involved in the 
predictions. When standard deviations are low, accurate SARM-
based potency predictions can be expected4.
Predictions based on conditional probabilities of activity
A conceptually different approach was developed for hit expansion 
from screening data based upon conditional probabilities of activ-
ity derived from SARMs, as outlined in Figure 3. In contrast to 
NBH-based prediction of numerical potency values, the conditional 
probability method can utilize approximate potency measurements 
(e.g., primary screening data) leading to a binary classification of 
Figure 3. Predictions based on conditional probabilities of activity. Steps and equations required to derive probabilities of activity from 
SARMs for prediction of virtual compound X are shown using a model SARM with nine compounds (A–I) that contain three cores (c1–c3) 
and four values (v1–v4). Matrix cells are color-coded according to compound activity (red, inactive; green, active). In the first step, initial 
class probabilities are calculated for all cores and values using equation 2 and 1, respectively. Value- and core-weighted matrices are then 
derived via equations 4 and 3. The class contribution of core c3 is obtained from the value-weighted matrix using equation 5. Analogously, 
the class contribution of value v1 is obtained from the core-weighted matrix using equation 6. The value and core class contributions are then 
normalized using equations 7 and 8. Finally, the activity probability px of 0.13 is obtained for X by combining the normalized core c3 and value 
v1 class probabilities using equation 9.
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inactive vs. active data set compounds and ensuing prediction of a 
probability of activity for VCs.
The conceptual basis of the approach is provided by the following 
ideas: based on the observed frequency of occurrence of given core 
and value fragments in active versus inactive compounds (in the 
following referred to as the active versus inactive class), probabili-
ties of activity and inactivity can be derived for cores and values. 
Importantly, the contributions of cores and values are thought to 
be influenced by each other because compounds are represented 
in SARMs as combinations of individual core and value fragments. 
Considering the conditional nature of core and value contributions 
to activity, initial probabilities are weighted to derive class probabil-
ities for any core and value. For a given VC, probabilities of its core 
and value are then combined to yield a final probability of activity.
Key steps of the methodology are summarized in Figure 3 (and 
for each step, the respective equation is provided). To illustrate the 
approach in an intuitive manner, we will go through an exemplary 
probability calculation for a given VC, guided by Figure 3.
Core and value class probabilities
The SARM in Figure 3 contains nine compounds (A–I) that comprise 
three cores (c1–c3) and four values (v1–v4). The probability of activ-
ity will be predicted for virtual compound X that shares core c3 with 
compounds G, H, and I and value v1 with compounds A and D.
Given the distribution of individual values v and cores c in active 
and inactive compounds, probabilities of activity and inactivity are 
calculated using equation 1 and equation 2. Here, P(y|v) and P(y|c) 
are the conditional probabilities that describe how likely it is to 
observe a given specific class y ∈{active, inactive} for a value v and 
a core c, respectively. If c(x), v(x), y(x) is the core, value, and class of 
a given compound x, we can express the conditional probabilities 
as the fraction of compounds with a core c or value v and class y 
relative to all compounds containing this core or value. In case of 
value v1, both class probabilities are equal (i.e., 1/2) because v1 is 
contained in one active and one inactive compound. By contrast, 
the probability of inactivity is two times higher for core c3 than its 
probability of activity (2/3 vs. 1/3).
Core- and value-weighted matrices
These initial estimates are further refined by taking information 
from all SARM compounds into account. For this, the inverse 
of value and core class probabilities is used to derive the value-
weighted matrix and core-weighted matrix, respectively. In case 
of the value-weighted matrix, the inverse class probabilities of 
the values are mapped to the compounds that represent the corre-
sponding value and class. Analogously, the core-weighted matrix 
is derived by mapping the inverse class probabilities of the cores 
to the compounds that represent the corresponding core and class. 
The value-weighted matrix results from the assignment of a weight 
to each compound using equation 3 and the core-weighted matrix is 
obtained using equation 4.
Refinement of core and value class contributions
In this step, core probabilities using value-weighted matrices and 
value probabilities using core-weighted matrices are derived. The 
underlying idea is to statistically assess if a core or value contrib-
utes more to activity or inactivity. This rationalizes the calculation 
of weights from the previous step: the less frequently observed 
class for a core or value is assigned a higher weight, which leads 
to a larger class contribution of the corresponding value or core 
of a compound, respectively. For example, the class probability of 
core c3 is updated by considering information from values v2, v3, 
and v4 in compound G, H, and I, respectively. All compounds con-
taining value v2 are active (2/2); hence, the core class probabili-
ties of compounds B and G are assigned a weight of 1.0 (through 
value-weighting). For value v3, the compounds show equal class 
frequency of (in)activity (1/2); thus, both active and inactive com-
pounds are assigned the same weight of 2.0. Finally, two of three 
compounds containing value v4 are inactive. Accordingly, inac-
tive compound I receives a lower weight of 1.5 indicating that its 
inactivity is more likely due to v4. It follows that with increasing 
frequency of inactivity for a given value, core weights of inactive 
compounds decrease (and vice versa), indicating that the value is 
likely to be responsible for inactivity. Analogous considerations 
apply to assess probabilities of activity.
From the value-weighted matrix, core class contributions are calcu-
lated with equation 5. For core c3, contributions of 0.34 and 1.12 to 
activity and inactivity are obtained, respectively, using a smoothing 
factor of α=0.1 (this factor is applied to prevent zero probabilities 
when no compound is available to represent a possible core or value 
class):
                             
3
0.1 1.0
( ) 0.34
0.2 3c
C act += =
+
3
0.1 2.0 1.5
( ) 1.12
0.2 3c
C inact + += =
+
Through normalization using equation 7 core class probabilities 
between 0 and 1 are obtained; for c3 values of 0.23 (activity) and 
0.76 (inactivity).
Analogously, value class probabilities are refined using the core-
weighted matrix (generated using equation 4). For example, class 
probabilities of value v1 are adjusted by considering information 
from cores c1 and c2 in compounds A and D that contain v1. Com-
pound A is active and belongs to the majority class of c1 and is thus 
assigned a lower weight than D, which is inactive and belongs to 
the minority class of c2. The higher weight assigned to compound 
D means that its inactivity is statistically more likely to result from 
value v1 than core c2. Weighted value class contributions calculated 
using equation 6 give activity and inactivity contributions of 0.72 
and 1.40, respectively, for value v1 (applying a smoothing factor 
of α=0.1):
                                 
1
0.1 1.5
( ) 0.72
0.2 2v
C act += =
+
1
0.1 3.0
( ) 1.40
0.2 2v
C inact += =
+
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Normalization using equation 8 then yields updated v1 class 
probabilities of 0.34 (activity) and 0.66 (inactivity).
Combined activity probability
Finally, the normalized core and value probabilities are combined 
via equation 9 yielding an activity probability p
x
 (ranging from 0 
to 1) for any core-value combination representing a VC. Increas-
ing p
x
 values indicate an increasing probability of activity. For 
classification, a threshold value of activity must be set (e.g., 0.5). 
In our example, the normalized core and value class probabilities 
for c3 and v1 result in an activity probability p
x
 of 0.13 for virtual 
compound X representing this core-value combination. Thus, given 
the low probability of activity, this VC is predicted to be inactive. 
In benchmark calculations on sets of known active and inactive 
compounds, conditional probability calculations yielded reason-
ably accurate predictions of activity, at least comparable to current 
state-of the-art machine learning approaches5.
Because the conditional probability approach is statistically 
grounded, prediction accuracy is expected to increase with sam-
ple sizes and matrix density6. Therefore, it makes sense to exclude 
SARMs from the calculations that contain only a small number of 
data set compounds or have limited row overlap (accounting for 
shared substitution patterns among structurally related series)6. 
Accordingly, SARMs with more than 50% row overlap are typically 
considered informative and prioritized for probability calculations.
Different from the NBH approach, the conditional probability 
method is generally applicable and not confined to compound 
subsets representing continuous SARs. Thus, QSAR applicability 
domain restrictions do not apply in this case.
Application
The conditional probability method has been used for activity 
predictions (hit expansion) starting from the results of a screen of 
the PRISM library of alpha helical turn mimetics11,12 carried out 
in search of new inhibitors of the Wnt/β-catenin protein-protein 
interaction and pathway13,14. The Wnt pathway is implicated in a 
variety of disease states including several forms of cancer. Conse-
quently, inhibitors of the Wnt/β-catenin interaction are thought to 
have high therapeutic potential13,14. PRISM’s current helix mimet-
ics library contains more than 10,000 small molecules with closely 
related scaffolds11,12 suitable for SARM analysis. These com-
pounds are analogs containing closely related scaffolds with three 
substitution sites each. The library screen was carried out using 
a luciferase reporter gene assay of the Wnt pathway15,16 and the 
stably transfected cell line Hek-293, STF1.111. Figure 4 summa-
rizes SARM analysis of the library and activity predictions. The 
library contained a total of 10,540 compounds that yielded 11,033 
stereochemistry-sensitive SARMs (i.e., matrices explicitly account-
ing for all stereoisomers) with a total of 231,143 VCs. This matrix 
distribution was solely determined by structural relationships 
between library compounds.
Figure 4. SAR matrix and prediction statistics. SAR matrix statistics for a library of alpha helical turn mimetics are provided and activity 
predictions for virtual compounds are summarized. For these predictions, conditional probabilities of activity were derived from library 
screening data.
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Screening of the library in the reporter gene assay yielded 64 active 
and 10,476 inactive compounds (applying a threshold of less than 
50% residual luciferase activity). Hence, only a limited number 
of compounds were classified as active applying this threshold. 
Active and inactive compounds were then mapped to SARMs and a 
subset of 1,049 informative matrices (with at least 50% row overlap) 
was selected that contained 10,504 VCs. Probability calculations 
predicted 28 VCs to be active. Twenty candidates were synthesized, 
re-screened, and tested in confirmatory assays, leading to the iden-
tification of five novel hits with activities in the low-micromolar 
range. These five novel actives were, by design, analogs of library 
compounds having previously unconsidered substitution patterns 
involving two different sites.
Data availability
In a deposition on the open access ZENODO platform17, the fol-
lowing data have been made available. Detailed probability calcu-
lations for the matrix in Figure 3 are provided in an excel sheet. 
Furthermore, SARMs generated from the PRISM library on which 
the calculations were based are made available without compound 
structures (compounds are represented by unique identification). On 
the basis of these SARMs, the predictions can be fully reproduced. 
Concluding remarks
In this contribution, we have discussed methodological advances 
for activity prediction on the basis of SARMs, which systematically 
account for structural/analog relationships in compound sets of any 
source, organize structurally related compound series, and yield 
virtual candidate compounds. In combination with the SAR matrix 
method, compound neighborhood analysis based upon Free-Wilson 
principles and derivation of conditional probabilities of activ-
ity are applicable to predict novel active compounds at different 
stages of chemical optimization efforts. The conditional probability 
approach detailed herein is particularly suitable for hit expansion 
and can be applied to raw screening data. Going beyond benchmark 
calculations, first prospective applications have yielded promis-
ing results. For example, screening data of the PRISM library of 
helix mimetics made it possible to prioritize a small number of 
candidate compounds for synthesis from a pool of ~10,000 pre-
selected VCs on the basis of only 64 preliminary screening hits. 
These predictions ultimately resulted in the identification of five 
new active compounds by considering only 20 candidates. These 
compounds provide new starting points for chemical optimiza-
tion efforts. Of course, further prospective validation studies will 
need to be performed to better understand the performance of 
SARM-based activity predictions for different compound classes, 
targets, and screening assays. However, considering the well-
defined scaffold-substituent patterns of compounds representing 
alpha helical turn mimetics and the systematic design of the library, 
which plays into the strength of the SARM approach, successful 
activity predictions are also anticipated for library screens using 
assay systems and targets engaged in other therapeutically relevant 
protein-protein interactions.
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This is an interesting upgrade of the SARM methodology, now endeavored with a probability-driven
activity prediction tool described in this paper. Unfortunately, I cannot recommend indexation as is,
because the methodology is not comprehensively described: some formulae embedded in a Figure are
never rigorously explained, except by means of some hand-waiving example. Therefore, I (hope I) got the
principle of the method - looks very much like naive Bayes to me. If so - does it do better than standard
naive Bayes, with some fragment count descriptors? Honestly, I could not write a piece of code
implementing it on the basis of what is said in the paper. Don't understand cryptic annotations like
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The SARM-based probability approach and Naïve Bayesian (NB) classification are both
probabilistic in nature and attempt to estimate the posterior probability of a given compound  tox
belong to a class i.e. ( | ). However, following Bayes’ theorem, NB modeling derives they,  P y  x
posterior from the prior and class likelihood. The class likelihood, ( | ), is estimated from theP x  y
data. By contrast, the SARM-based approach assigns weights to the cores (keys) based on
substituents (values) and vice versa. This is done under the assumption that either cores, values,
or their combination might be responsible for the activity. Thus, the approach estimates the
posterior from the data and then applies a re-weighting (refinement) scheme by calculating core
and value class contributions.
All methodological details of the SARM-based probability of activity approach are provided in
reference 5 of the paper. 
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This Method article mostly describes an extension of the SAR Matrix approach to predict active
compounds from many virtual candidates that are contained in matrices derived from compound libraries.
 
The new activity prediction method is generally applicable to screening data to facilitate hit expand and
can make use of approximate activity measurements such as % inhibition. This would be attractive in
practice.
 
The conditional probability method, which was first published in an informatics journal, is not trivial and
probably not easy to understand for many medicinal chemists.
Therefore, the authors were obviously motivated to make this prediction methodology accessible to wider
audience in screening and medicinal chemistry. They have done so by going step by step through
exemplary calculations that illustrate ideas behind this approach and show how active compounds are
predicted.
In addition, they report first practical applications that should make this method in combination with the
SAR matrix structure attractive to many.
Although the application on a library of helix mimetics is essentially proprietary (structures of active
compounds cannot be shown), the statistics of the predictions are interesting. Of thousands of virtual
compounds the SAR matrix approach generates for this library, only 28 were predicted to be active using
the new method when processing reporter gene assay data probing the Wnt pathway. Twenty of these
compounds were synthesized and tested and 5 new hits were identified with low-micromolar potency.
Clearly, if the combined SAR matrix / activity prediction approach produces similar results in additional
applications of this library or other screening libraries, it will be
rather useful for hit expansion.
Taken together, the authors have attempted to make a relatively complex computational approach easier
to appreciate by a screening or chemistry audience by providing easy to follow examples and practical
applications. This could hardly be accomplished in a specialized computational journal.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
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We thank the reviewer for pointing at a primary motivation for this publication and for emphasizing
accessibility to a wider than an expert computational audience. 
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Gupta-Ostermann's "follow-up" manuscript is well written and clearly laid out. I only have a few (minor)
recommendations, which I believe would help readers more easily replicate their work.
The added value of this manuscript lies in figure 3 where "conditional probabilities of activity" are
explained. The authors have explained conditional probabilities with figures, text and associated
mathematical equations and have even gone so far as to carry out the math for the weighted core class
contributions. For interested readers who want to implement the conditional probabilities concept in their
own research, I highly suggest that real (or toy) data be included, in the very least, as supplemental
material with all the data completely worked out, not just the weighted core class contributions. This would
allow one to implement the concept, carry out the math and compare the results to the published results
more easily. Additionally, although text is included to explain conditional probabilities, I found myself
having to read this section a few times to fully understand the clear impact this method could have. I think
this section needs to be expanded with more text.
Finally, although it is understandable that the work carried out herein with PRISM BioLab Corporation, is
proprietary, it is unfortunate that more information regarding the "twenty synthesized candidates" can not
be elaborated upon.  Any information regarding the similarity of these compounds to the actives (or even
the similarity range of the actives themselves) would be informative.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
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This interesting contribution by Bajorath nicely extends the idea of graphical methods for SARet al. 
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This interesting contribution by Bajorath nicely extends the idea of graphical methods for SARet al. 
analysis in computational medicinal chemistry. The SARM method was shown earlier to capture SAR
information from larger collections by matched molecular pairs (MMPs) and to present it in an intuitive
way. Furthermore the combination of large-scale SAR analysis with virtual compounds allows guiding
synthesis to explore straightforward ideas as direct outcome of SAR interpretation. Therefore this
approach is attractive to rapidly identify activity trends and cliffs.
The paper reports a conditional probability-based approach to activity prediction from SAR knowledge.
Such a conditional probability measures the probability of activity for one compound given that a
structurally related compound was active. Individual probabilities are extracted from rows and columns in
the underlying SARMs. While such a probabilistic approach only works for SARMs, which are sufficiently
populated and have shared substitution pattern, the approach is not restricted to compound subsets
representing continuous SAR only.
The prospective application of this interesting concept suffers from the lack of chemical structures, so that
the degree of similarity between actives and follow-up design cannot be assessed. Furthermore the
description of the HTS assay, substructure alerts, additional filtering, assay validation and retesting rates,
compound QCs for actives is missing. This makes it difficult to evaluate the true HTS outcome using
potentially noisy data for such a challenging PPI target.
To illustrate the value of the novel activity estimation approach from matrices, it might be useful
constructing a standard 2D-QSAR model and check is for predictivity of the synthesized top-20 design
proposals in comparison to the matrix-derived conditional probability. It might be of interest to see, how
robust both approaches work with noisy primary screening data.
The manuscript title and abstract cover the content well. The chemoinformatics approach is clearly
described and can most likely be reproduced. As this is not the case for the HTS actives and the assays
for this study, the results will be difficult to reproduce. The authors might also want to mention, whether
software tools from their study are available to the public.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
Author Response (  and  ) 09 Apr 2015Member of the F1000 Faculty F1000Research Advisory Board Member
, Department of Life Science Informatics, B-IT and LIMES Institutes, RheinischeJürgen Bajorath
Friedrich-Wilhelms-Universität Bonn, Germany
A conventional QSAR model has been difficult to derive in this case because of the rather
approximate nature of activity annotations obtained from raw screeing data. Instead, a
cross-validated binary QSAR model has been generated from the screening data using the
Molecular Operating Environment (version 2013.08; Chemical Computing Group Inc., Montreal,
Canada) and applied to predict the activity state of the 20 test compounds, producing an accuracy
of 0.65 for active and inactive compounds. 
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CHAPTER 7: SUMMARY
Summary
This study reports the first prospective application of the SAR matrix-derived
conditional probabilities for hit expansion. From the PRISM library of helix
mimetics with approximately 10,000 compounds, out of which only 64 were ac-
tive, a pool of approximately 10,000 VCs was obtained using the SARM method.
Predictions on these resulted in the prioritization of 20 VCs, which were syn-
thesized and tested. From these ultimately five new actives were identified.
This study demonstrates the successful application of the method for data sets
comprising of well-defined scaffold-substituent patterns. Further studies would
be required to better understand the performance of SARM-based probabil-
ity method on data sets representing different compound classes, targets and
screening assays. My contribution to this study was to carry out the activity
predictions and to analyze the data.
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Chapter 8
Conclusions
The major objectives of this dissertation have been the development of compu-
tational methods for SAR analysis and activity predictions to aid in prospective
compound design. A number of representative studies have been presented.
In the first study, a newly designed activity landscape model, LASSO graph,
was introduced that utilizes molecular frameworks to organize compounds hier-
archically into sets of scaffolds and cyclic skeletons (CSKs). The design scheme
facilitates the “forward-backward” exploration of SARs and reveals signature
SAR patterns. The graph topology is compact and shows global and local SAR
trends in compound data (Chapter 2).
The remainder of the dissertation was dedicated to develop methodological
advancements of the SAR matrix method. Activity landscapes are descriptive in
nature. They reveal SAR trends in compound data but do not guide compound
design directly. SARMs represent a crucial data structure that expand the
chemical space envelope of a compound data, giving rise to various unexplored
compounds. These virtual compounds are novel design suggestions and can be
prioritized for synthesis and testing. Thus, SARMs provide a close link between
descriptive SAR analysis and prospective compound design. New methodologies
were incorporated in the SARM method to enhance its applicability in the fields
of chemogenomics and medicinal chemistry (Chapter 3).
The aim of the original SARM methodology was large-scale SAR analysis
of structurally-related compound series active against a given target. Depart-
125
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ing from SAR analysis, the SARM-based structural organization scheme was
adapted for chemogenomics applications, in which compound-target interac-
tions are systematically explored (Chapter 4). These matrices, called the com-
pound series matrices, identified closely related analog series with multi-target
activities in the public domain. Compound series matrices are useful in ex-
ploring compound promiscuity patterns, thereby aiding in the identification of
compounds that are attractive for testing against additional targets. Virtual
compounds resulting in these matrices can be useful to design novel compounds
with desired activity profiles.
Utilizing matched molecular pair relationships in SARMs, an approach
was developed to predict compound activities of virtual compounds (Chap-
ter 5). Here, neighborhoods of virtual compounds were systematically utilized
as “mini-QSAR” models for activity prediction. Multiple neighborhoods act as
a diagnostic for the local SAR environments of the virtual compounds. The
approach resulted in accurate activity predictions for compounds mapping to
continuous SAR regions. Compounds mapping to discontinuous SAR regions
fall outside the applicability domain of the methodology. This approach is
not applicable to screening sets where explicit activity values are not available.
Therefore, a conceptually different approach was developed for hit expansion
from screening data based upon conditional probabilities of activity derived
from SARMs (Chapter 6). The method utilizes a binary classification of in-
active vs. active data set compounds to predict probability of activity for
virtual compounds. The method performs comparable to state-of-the-art ma-
chine learning methods and has low computational complexity. This method
expands the utility of the SARMs from hit-to-lead and lead optimization data
to screening libraries.
Finally, a prospective application of the conditional probability-based pre-
diction approach on the SARM method is introduced (Chapter 7). The study
was carried out on the PRISM library of alpha helical turn mimetics, where
well-defined scaffold-substituent patterns existed. Out of approximately 10,000
original compounds with 64 actives, approximately 10,000 virtual compounds
were generated and pre-selected. 20 of these were predicted to be active. Af-
ter synthesis of these 20, five novel actives with IC50 values in the micromolar
126
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range were found. This study provides the first prospective application of this
method beyond benchmarking.
In conclusion, this dissertation reports novel computational methods for
SAR analysis and activity prediction. Major methodological advancements
were developed on the SAR matrix method, thereby rendering it highly attrac-
tive for practical applications.
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